[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 721
1. Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS: Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res; 2009 Dec;2(6):317-323

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma.
  • BACKGROUND: The purpose of this study is to evaluate perioperative morbidity, mortality and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.
  • METHODS: Fifty patients with transmural advanced gastric adenocarcinoma underwent curative resection in our clinic.
  • The records of the patients were reviewed and the prognostic factors such as age, gender, location and size of the tumor, type of surgery, blood transfusion, depth of tumor invasion, lymph node metastases, stage of the disease, grading, vascular invasion, lymph vessel invasion, characteristics of the tumor according to Lauren's classification, and lymph node ratio were evaluated by using statistical methods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990200.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Advanced / Gastric Cancer / Morbidity / Mortality / Survival / Transmural
  •  go-up   go-down


2. Ilias EJ, Malheiros CA, Kassab P, Castro OA: [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma]. Rev Assoc Med Bras (1992); 2006 Jul-Aug;52(4):270-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma].
  • [Transliterated title] Linfadenectomia no adenocarcinoma gástrico.
  • BACKGROUND: To simulate a D1 lymphadenectomy in 57 patients who had already been submitted to D2 lymphadenectomy, and analyze stage migration using the Japanese Gastric Cancer Association (JGCA) staging system.
  • All patients were re-staged based on the new data, in order to evaluate the stage migration according to the JGCA staging system.
  • In IA, IB and II tumors, there were no changes in the stage after simulation of D1 lymphadenectomy.
  • In ten IIIA tumors, three migrated to stage II and IB; in 21 tumors staged as IIIB, a migration was observed in 18; all stage IV tumors migrated to IIIB after the D1 simulation.
  • CONCLUSION: a) D2 lymphadenectomy is important for the correct staging of gastric cancer;.
  • b) simulation of D1 lymphadenectomy changed the stage of advanced tumors, particularly in stages IIIA, IIIB, and IV;.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Lymph Node Excision / methods. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967148.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF: Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg; 2006 Feb;243(2):189-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma.
  • OBJECTIVE: For patients with laparoscopic stage M1 gastric adenocarcinoma, no resection of the primary tumor, and systemic chemotherapy, this study investigated the incidence of subsequent palliative intervention and survival.
  • SUMMARY BACKGROUND DATA: Laparoscopy was performed for patients with computed tomography scan stage M0 disease and no significant obstruction or bleeding.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):1183-8 [9756030.001]
  • [Cites] J Clin Gastroenterol. 1998 Jul;27(1):63-6 [9706773.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1083-7 [10460650.001]
  • [Cites] Br J Surg. 2000 Oct;87(10):1281-3 [11044150.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):780-4 [11087645.001]
  • [Cites] Hepatogastroenterology. 2001 Jan-Feb;48(37):285-9 [11268986.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):393-9 [8790853.001]
  • [Cites] Gastrointest Endosc. 1996 Nov;44(5):536-40 [8934158.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Jan;10(1):185-201 [11406458.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1219-21 [11677934.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):72-8 [11808972.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):460-6 [11952588.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):471-5 [11952590.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):696-703 [12167585.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):459-83, xiii [12424863.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):654-63 [12839850.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):1013-21 [15194084.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1195-200 [6186352.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Surg Gynecol Obstet. 1987 Feb;164(2):151-4 [2433778.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):381-6 [2918333.001]
  • [Cites] Surgery. 1991 Nov;110(5):820-3 [1948650.001]
  • [Cites] Gastrointest Endosc. 1992 May-Jun;38(3):314-8 [1607082.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Surgery. 1996 Jun;119(6):611-4 [8650600.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):434-40 [9469326.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • (PMID = 16432351.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1448917
  •  go-up   go-down


Advertisement
4. Kavgaci H, Reis A, Ozdemir F, Bektas O, Arslan M, Aydin F: Carcinoma erysipelatoides resulting from gastric adenocarcinoma: an unusual clinical presentation. Med Princ Pract; 2005 Jan-Feb;14(1):61-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma erysipelatoides resulting from gastric adenocarcinoma: an unusual clinical presentation.
  • OBJECTIVE: To report a rare case of carcinoma erysipelatoides on the laryngeal skin caused by stomach adenocarcinoma.
  • CLINICAL PRESENTATION AND INTERVENTION: A 48-year-old male, who had undergone a gastrectomy 18 months prior to admission for stage IIIA gastric adenocarcinoma, presented with a reddish induration of the cervical skin, lymphadenopathy in both supraclavicular areas and widespread subcutaneous nodules.
  • CONCLUSION: We recommend combination chemotherapy in patients with cutaneous metastasis of gastric adenocarcinoma as a safe and effective treatment.
  • [MeSH-major] Adenocarcinoma / secondary. Head and Neck Neoplasms / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608485.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


5. Necula A, Vlad L, Iancu C, Munteanu D, Puia C, Bălă O, Pop F, Radu H, Al-Hajaar N, Osian G, Graur F, Furcea L, Stanca M, Molnar G, Mocan T: [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma]. Chirurgia (Bucur); 2008 Mar-Apr;103(2):181-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma].
  • [Transliterated title] Aspecte clinice cu implicaţie prognostică în cancerul gastric--analiză a 468 cazuri de adenocarcinom gastric.
  • We made a retrospective analysis of a group of 468 patients with gastric adenocarcinoma which were operated in the 3rd Surgical Clinic--Cluj Napoca--01.01.1998-31.12.2003.
  • Patients in pTNM 0 stage were significantly younger than the rest of patients, with an average of 7.5 years.
  • The male/female ratio was 1.7:1, this ratio being significantly higher in cases with proximal gastric cancers.
  • There was not found any significant correlation between the interval : onset of symptoms and surgery, and pTNM stage.
  • This significant group of patients studied has maintained characteristics encountered in populations with higher incidence of gastric adenocarcinoma, men being more frequently affected, distal localization and intestinal histologic type being encountered more frequently.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457096.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


6. Maduekwe UN, Lauwers GY, Fernandez-Del-Castillo C, Berger DL, Ferguson CM, Rattner DW, Yoon SS: New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma. Ann Surg Oncol; 2010 May;17(5):1267-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma.
  • BACKGROUND: The American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) staging system for gastric cancer incorporates the absolute number of metastatic lymph nodes (N status) and is optimally used when >or=15 nodes are examined.
  • METHODS: Two hundred and fifty seven patients with gastric adenocarcinoma who underwent gastric resection between 1995 and 2005 at our institution were examined.
  • CONCLUSIONS: The use of N status for staging patients undergoing primarily D1 lymphadenectomy results in significant stage migration due to varying numbers of nodes examined.
  • Use of N ratio reduces stage migration and may be a more reliable method of staging these patients.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1490-3 [9552056.001]
  • [Cites] World J Surg. 2009 Oct;33(10):2106-11 [19636611.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1408-12 [11578301.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):278-86 [11923135.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):775-84 [12374661.001]
  • [Cites] Jpn J Clin Oncol. 2002 Sep;32(9):363-4 [12417603.001]
  • [Cites] Expert Opin Pharmacother. 2003 Jul;4(7):1083-96 [12831335.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1077-85 [14597447.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] Jpn J Surg. 1973 Mar;3(1):61-71 [4803902.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Surg Gynecol Obstet. 1990 Jun;170(6):488-94 [2343364.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):19-25 [7799019.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] World J Surg. 1997 Jul-Aug;21(6):622-7; discussion 627-8 [9230660.001]
  • [Cites] Oncologist. 2009 Sep;14(9):871-82 [19738001.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):119-22 [10027374.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):59-66 [15642427.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7114-24 [16192595.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1576-84 [16317484.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Ann Surg Oncol. 2006 Sep;13(9):1175-81 [16947008.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):78-85 [17242674.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):543-52 [17414602.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):95-101 [17443727.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):132-5 [17979134.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):159-65 [17566691.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):319-26 [19050970.001]
  • [Cites] Hepatogastroenterology. 2008 Nov-Dec;55(88):2287-90 [19260524.001]
  • [Cites] Ann Oncol. 2009 May;20(5):897-905 [19179553.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [CommentIn] Ann Surg Oncol. 2010 May;17(5):1257-8 [20140527.001]
  • [CommentIn] Ann Surg Oncol. 2010 Jun;17(6):1718; author reply 1719 [20397057.001]
  • (PMID = 20099040.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR025757; United States / NCRR NIH HHS / RR / 1 KL2 RR025757-0 1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS480723; NLM/ PMC3785005
  •  go-up   go-down


7. Necula A, Vlad L, Iancu C, Munteanu D, Puia C, Bălă O, AlHajaar N, Pop F, Radu H, Osian G, Graur F, Furcea L, Stanca M, Molnar G, Mocanu L: [Morbidity and mortality in gastric cancer surgery--analysis of 468 cases with gastric adenocarcinoma]. Chirurgia (Bucur); 2008 Sep-Oct;103(5):529-37
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morbidity and mortality in gastric cancer surgery--analysis of 468 cases with gastric adenocarcinoma].
  • [Transliterated title] Morbiditate şi mortalitate în chirurgia cancerului gastric--analiza a 468 cazuri de adenocarcinom gastric.
  • The aim of this study is to evaluate the morbidity and mortality in the surgical treatment of gastric cancer and the factors that could influencing them.
  • We made a retrospective analysis of a group of 468 patients with gastric adenocarcinoma which have been operated in the 3RD Surgical Clinic-Cluj Napoca--01.01.1998-31.12.2003.
  • We analyzed parameters related to patient, pTNM stage and type of treatment.
  • Morbidity was significantly higher in these circumstances: elder patients, cases with lower serum levels of hemoglobin and total proteins, after Billroth II procedures; we found no significant differences of morbidity depending on gender, pTNM stage, type of intervention: simple or multiorgan resection, subtotal or total gastrectomy, radical or palliative procedure or only exploratory laparotomy, presence or absence of splenectomy or caudal pancreatectomy, D1 or D2 lymphadenectomy (in radical procedures), palliative resection or gastrojejunal bypass.
  • Elder patients and male patients have had a mortality significantly higher; we found no significant differences of mortality depending on serum levels of hemoglobin and total proteins, pTNM stage, type of intervention: simple or multiorgan resection, subtotal or total gastrectomy, radical or palliative procedure or only exploratory laparotomy, presence or absence of splenectomy or caudal pancreatectomy, D1 or D2 lymphadenectomy (in radical procedures), type of restoring of the digestive continuity after subtotal gastrectomy, palliative resection or gastrojejunal bypass.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260628.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


8. Koufuji K, Shirouzu K, Aoyagi K, Yano S, Miyagi M, Imaizumi T, Takeda J: Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction. Kurume Med J; 2005;52(3):73-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction.
  • To clarify the optimal operative procedure for gastric adenocarcinoma involving the esophago-gastric junction (EGJ), we investigated 49 cases with an upper gastric cancer invading the esophagus who underwent surgical treatment in our department during the period from 1991 to 2000.
  • Proximal gastrectomy was performed in 6 cases at the early stage and in 10 cases at the advanced stage with distant metastasis (M1).
  • Total gastrectomy was done in 33 cases at the advanced stage, and 3 of these 33 cases had metastasis to the parapyloric lymph nodes.
  • Tumors were stage I in 8 cases, II in 5 cases, III in 13 cases and IV in 23 cases, and the curability was categorized as A in 8 cases, B in 20 and C in 21.
  • The overall 5-year-survival rate was 25%, and the rates according to cancer stage were 86% for stage I, 40% for stage II , 21% for stage III and 0% for stage IV.
  • The 5-year survival rates of cases at stage II and III were 33% for cases using the left thoraco-abdominal approach and 28% for cases with the abdominal approach.
  • Based on these results, we recommend distal esophagectomy with total gastrectomy, and occasional combined resection of the spleen and the diaphragm through a left thoraco-abdominal approach for advanced gastric adenocarcinoma involving the EGJ.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422172.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Adán-Merino L, Gómez-Senent S, Froilán-Torres C, Suárez J, Martín- Arranz E, Larrauri J, Mora-Sanz P, Segura-Cabral JM, Aldeguer-Martinez M: [Gastric adenocarcinoma in young adults; comparative study with older patients]. Rev Gastroenterol Mex; 2010;75(3):253-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in young adults; comparative study with older patients].
  • [Transliterated title] Adenocarcinoma gástrico en adultos jóvenes; estudio comparativo con pacientes mayores.
  • BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age.
  • The aim of thisΩ demographic, clinicopathological and prognosis of gastric cancer in young patients and to compare their features with the behavior in elder adults.
  • The most common T stage in young and elder patients was T3 (52.9% and 56.7% respectively).
  • CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959173.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


10. Căinap C, Părău A, Muntean A, Hodorog A, Vlad L: [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy]. Chirurgia (Bucur); 2010 Jan-Feb;105(1):31-6
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy].
  • [Transliterated title] Chimioterapia de generaţie nouă in cancerul gastric operat--o alternativă la chimioterapia clasică.
  • Gastric cancer remains one of the most difficult tumour type despite his relative reduction of his global incidence, it remains on of the most deadly cancer.
  • The latest advances in therapy of the gastric cancer ameliorate the results in terms of survival.
  • In our prospective, non-randomized study, we enrolled 40 patients with gastric adenocarcinoma stage IB to IV (M0) who were surgically treated, treated with chemoradioterapy, but with chemotherapy modified by ECX (epirubicine, cisplatine, xeloda) which is now considered standard in metastatic setting.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405677.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Togănel RD, Muntean V, Fabian O: [The role of laparoscopic peritoneal cytology in the diagnosis and treatment of gastric cancer]. Chirurgia (Bucur); 2010 Jan-Feb;105(1):113-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of laparoscopic peritoneal cytology in the diagnosis and treatment of gastric cancer].
  • [Transliterated title] Rolul citologiei peritoneale laparoscopice in algoritmul de diagnostic si tratament al cancerului gastric.
  • Gastric cancer is one of the most frequent gastro-intestinal neoplasia.
  • The prognosis of this disease is correlated with tumor stage, surgery being the only method which offers an important improvement in survival rate.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Laparoscopy. Peritoneal Lavage. Peritoneum / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405691.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


12. Siewert JR, Stein HJ, Feith M: Adenocarcinoma of the esophago-gastric junction. Scand J Surg; 2006;95(4):260-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophago-gastric junction.
  • BACKGROUND: The border between the esophagus and stomach gives rise to many discrepancies in the current literature regarding the etiology, classification and surgical treatment of adenocarcinoma arising at the esophago-gastric junction.
  • We have consequently used the AEG-criteria (adenocarcinoma of the esophago-gastric junction) for classification and have based the selection of the surgical approach on the anatomic topographic subclassification.
  • METHODS: In the following we report an analysis of a large and homogeneously classified population of 1602 consecutive patients with adenocarcinoma of the esophago-gastric junction, with an emphasis on the surgical approach, the pattern of lymphatic spread, the outcome after surgical treatment and the prognostic factors.
  • RESULTS: The study confirms the marked differences in sex distribution, associated specialized intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, lymphatic spread, and stage between the three tumor entities.
  • CONCLUSION: The classification of adenocarcinomas of the esophago-gastric junction in three types, AEG type I, type II and type III shows marked differences between the tumor entities and is recommended for selection of a proper surgical approach.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / surgery. Esophageal Neoplasms / classification. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / classification. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249275.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Mirarchi M, De Raffele E, Lega S, Calculli L, Vaccari S, Cola B: [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient]. Chir Ital; 2009 May-Jun;61(3):357-67
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient].
  • [Transliterated title] Adenocarcinoma del colon e neoplasia papillare intraduttale mucinosa multifocale sincrona del pancreas in un paziente anziano: caso clinico e revisione della letteratura.
  • A 78-year-old man presented with rectal bleeding which led to the diagnosis of a stenosing adenocarcinoma of the sigmoid colon.
  • A two-stage procedure was planned: an R0 sigmoid resection was undertaken first with an uneventful postoperative course.
  • Forty-five days later a pancreaticoduodenectomy was performed and the postoperative course was again uneventful apart from delayed gastric emptying.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694240.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Nazli O, Yaman I, Tansuğ T, Işgüder AS, Bozdag AD, Bölükbaşi H: Palliative surgery for advanced stage (stage IV) gastric adenocarcinoma. Hepatogastroenterology; 2007 Jan-Feb;54(73):298-303
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative surgery for advanced stage (stage IV) gastric adenocarcinoma.
  • BACKGROUND/AIMS: The factors that effect resectability, major morbidity, early mortality, and survival in advanced stage gastric adenocarcinoma patients are evaluated.
  • METHODOLOGY: Records of 74 patients that underwent surgery for stage IV gastric adenocarcinoma in the Third Surgical Clinic of Izmir Atatürk Training Hospital between January 1997 and January 2004 were reviewed retrospectively.
  • Although early mortality was high in the palliative resection group, survival (mean 10.4 months, longest 25 months) was better compared to that of the unresectable gastric cancer group (mean 3.5 months, longest eight months).
  • CONCLUSIONS: A palliative gastric surgery may be applied to improve prognosis of advanced gastric cancer patients, even at the presence of peritoneal dissemination, hepatic metastases, N3 lymph node involvement, adjacent organ invasion, or poor differentiation of the tumor.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Palliative Care. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419279.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Fahlke J, Ridwelski K, Florschuetz A, Kettner E, Leithaeuser M, Kroehning H, Stuebs P, Zierau K, Lippert H: Cetuximab plus docetaxel-cisplatin (DC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e15592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab plus docetaxel-cisplatin (DC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase II study.
  • : e15592 Background: Based on promising published data, this multicenter, phase II study was initiated to investigate a combined treatment using DC and cetuximab in the first-line setting for patients with gastric cancer.
  • METHODS: Patients aged 18-75 years with stage III (T4, nonresectable) or stage IV gastric cancer, ECOG performance status (PS) ≤2, and life expectancy ≥3 months were recruited to receive cetuximab (400 mg/m<sup>2</sup> on day 1 then 250 mg/m<sup>2</sup> q1w) and DC (D 75 mg/m<sup>2</sup> and C 75 mg/m<sup>2</sup>; both as 1-h infusions on day 1 and then q3w).
  • RESULTS: Preliminary data are available for 30 patients; median age 64 [range: 40-73] years; median ECOG PS 1 [range: 0-2]; adenocarcinoma 87%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962888.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. de Bruin MA, Kunz PL, Sharma VB, Norton JA, Bastidas J, Chang DT, Koong AC, Koong AC, Balise RR, Ford JM, Fisher GA: Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. J Clin Oncol; 2009 May 20;27(15_suppl):e15674

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience.
  • : e15674 Background: The standard of care for the adjuvant treatment of resected gastric or gastroesophageal junction (GEJ) adenocarcinoma in the U.S. is post-operative 5FU and radiotherapy per the MacDonald regimen.
  • METHODS: A retrospective review was performed of patients at SCC with T2-T4 or node positive gastric or GEJ cancer who underwent surgery with curative intent, and then received the following treatment.
  • At week 8, infusional 5FU or capecitabine was combined with external beam radiotherapy to the gastric bed for five weeks (total 4,500 cGy).
  • Thirty-nine had gastric and 10 had GEJ cancers.
  • The percentage of patients alive by stage was 100% (4/4) for stage IB, 62% (8/13) for stage 2, 53% (9/17) for stage IIIA, 33% (2/6) for stage IIIB and 22% (2/9) for stage IV.
  • CONCLUSIONS: Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine after curative resection of gastric and GEJ cancer was well tolerated and yielded survival results similar to historical data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962823.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lu M, Shen L: Recurrence patterns of Chinese patients with gastric cancer after complete resection. J Clin Oncol; 2009 May 20;27(15_suppl):e15667

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns of Chinese patients with gastric cancer after complete resection.
  • : e15667 Background: Recurrence after radical resection was the most important factor that influence the prognosis of patients with gastric adenocarcinoma.
  • Focusing on the clinicopathologic features and recurrence patterns, this study aims to find the characteristics of recurrence pattern and the predictive factors of gastric cancer patients in China.
  • METHODS: This is a retrospective analysis of the gastric adenocarcinoma patients who accepted adjuvant treatment and follow up in our medical department after R0 resection.
  • Locoregional recurrence was defined as dominant masses in the gastric bed, regional nodes or anastomotic recurrence.
  • Distant recurrence was significant associated with male gender, advanced T-stage, positive lymph nodes and number of lymph node dissection<15; female gender, poor differentiation and advanced T-stage were high risk factors of peritoneal recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold PJ, Corless CL: Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol; 2009 May 20;27(15_suppl):4513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).
  • METHODS: Eligibility: clinical stage II/III EA, ≥ 18 years, Zubrod PS ≤ 2, standard hematologic/non-hematologic values, and tumor < 2 cm into the gastric cardia.
  • The trial used a 2-stage design; the trial was halted at 45 PTS to review pCR rate; it reopened to full accrual.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Moon Y, Rha S, Jeung H, Shin S, Yoo N, Roh J, Noh S, Chung H: Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer.
  • : e15521 Background: Little is known about data on subsequent chemotherapy (CTx) following 1<sup>st</sup>-line CTx in stage IV gastric cancer.
  • The purpose of this study was to analyze the natural history of stage IV gastric cancer with sequential CTx Methods: A total of 532 patients (pts) with unresectable gastric adenocarcinoma were studied.
  • 87%/47%/23% of the whole pts received 1<sup>st</sup>/2<sup>nd</sup>/3<sup>rd</sup>-line CTx, respectively.
  • Response and disease control rates were 21.7%/12.5%/11.8% and 79.4%/56.3%/49.4% for 1<sup>st</sup>/2<sup>nd</sup>/3<sup>rd</sup> lines, respectively.
  • Median progression-free and overall survivals from CTx were 5.5/3.4/2.5 months and 12.1/7.9/5.5 months for 1<sup>st</sup>/2<sup>nd</sup>/3<sup>rd</sup> lines, respectively.
  • The most common cause of discontinuation of CTx was disease progression (68%/74%/70%) followed by pt's refusal (22%/13%/12%) for 1<sup>st</sup>/2<sup>nd</sup>/3<sup>rd</sup> lines, respectively.
  • Prognosticators were performance status, histology, metastatic site, and CTx before 1<sup>st</sup> or 2<sup>nd</sup> line.
  • CONCLUSIONS: When pts with unresectable gastric cancer were managed with a strategy of maximal administration of CTx, a considerable number of pts could receive 2<sup>nd</sup> or 3<sup>rd</sup> line CTx, showing modest activity.
  • Our data on the natural history of stage IV gastric cancer with sequential CTx may suggest that clinical trials can be performed in a 2<sup>nd</sup> or 3<sup>rd</sup> line setting as well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lee J, Kang W, Lim D, Park J, Park Y, Lim H, Sohn T, Noh J, Bae J, Kim S: Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis.
  • : 4537 Background: Although the adjuvant chemoradiation therapy has gained popularity and has become the standard of care in patients with resected gastric cancer in U.S., the role of chemoradiation therapy after extended D2 dissection has been questioned.
  • We conducted a phase III trial to compare capecitabine/cisplatin (XP) vs XP + radiotherapy (RT) in curatively D2 resected gastric cancer patients in terms of disease free survival and overall survival.
  • METHODS: Eligibility criteria were as follows: stage Ib (T1N1, T2bN0) - IV (M1 excluded), curatively ≥ D2 resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962988.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • METHODS: We analyzed 54 cases of cytological confirmed gastric LMC at 4 institutions from 1994 to 2007.
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The clinical or pathologic TNM stages of the primary gastric cancer were IV in 38 patients (70%).
  • Clinically, initial advanced stage was predictive value of poor prognosis (P=0.009).
  • CONCLUSIONS: Although gastric LMC has dismal prognosis, IT and IV chemotherapy could be help to extend survival duration of gastric LMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kim S, Kim J, Chae Y, Sohn S, Moon J, Kang B, Chung H, Yu W, Baek J: Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer.
  • : e15638 Background: The present study analyzed the functional insertion/deletion polymorphism in the promoter region of NKFB1 gene and their impact on the prognosis for patients with gastric adenocarcinoma.
  • METHODS: Five hundred and three consecutive patients with surgically resected gastric adenocarcinoma were enrolled in the present study.
  • No correlation was observed between the frequency of the genotype or allele and the T, N, or M stage.
  • The multivariate survival analysis showed no association between the NFKB1 -94 insertion/deletion promoter polymorphism and the disease-free survival or overall survival of the patients with gastric cancer.
  • CONCLUSIONS: The functional NFKB1 promoter polymorphism was not found to be a prognostic marker for Korean patients with surgically resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Alici S, Kaya S, Izmirli M, Tuncer I, Doğan E, Ozbek H, Sayarlioglu H: Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit; 2006 May;12(5):CR221-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma.
  • BACKGROUND: Prognosis in patients with gastric cancer is determined by the tumor itself, as well as certain patient-related factors.
  • MATERIAL/METHODS: In this study, 138 patients with high-grade gastric adenocarcinoma who were admitted to our hospital between September 1999 and April 2002 were retrospectively evaluated in terms of the effects of clinicopathological parameters and treatment approaches on survival by single and multiple variable analyses.
  • Patients histopathologically diagnosed as having gastric adenocarcinomas with stage IV M0 (without distant organ metastasis) or stage IV M1, (with distant organ metastasis) were included in the study.
  • With single variable analysis, body mass index (BMI), clinical stage, surgery, type of surgery, and serum level of albumin were significant prognostic factors related to overall median survival time.
  • Gender, clinical stage, surgery, type of surgery, hemoglobin concentration, and serum level of albumin were found to be significant prognostic factors related to survival without progression (p < 0.05).
  • CONCLUSIONS: No surgical treatment, palliative surgery instead of radical surgery, and BMI below 20 on first admission were determined as poor prognostic factors related to survival in patients with high-grade gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Stomach Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641880.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


24. Khosravi Shahi P, Díaz Muñoz de la Espada VM, García Alfonso P, Encina García S, Izarzugaza Perón Y, Arranz Cozar JL, Hernández Marín B, Pérez Manga G: Management of gastric adenocarcinoma. Clin Transl Oncol; 2007 Jul;9(7):438-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of gastric adenocarcinoma.
  • Gastric adenocarcinoma is the second most common cause of cancer death worldwide.
  • The prognosis for patients with gastric adenocarcinoma depends on the stage of the disease at the time of diagnosis and treatment.
  • Early gastric cancer, limited to the mucosa and submucosa, is best treated surgically and has a five-year survival rate of 70-95%.
  • The management of localised gastric adenocarcinoma is complex, and at present there is proven benefit of both preoperative chemotherapy and postoperative chemoradiotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8(4):396-9 [9180395.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):655-60 [16618532.001]
  • [Cites] Eur J Surg Oncol. 1986 Sep;12(3):247-50 [3758361.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1976-83 [15928658.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] World J Surg. 1987 Aug;11(4):418-25 [3630186.001]
  • [Cites] Semin Oncol. 1985 Mar;12 (1):11-8 [3975641.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):383-7 [12598342.001]
  • [Cites] World J Surg. 2001 Aug;25(8):985-90 [11571980.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1249-54 [6491703.001]
  • [Cites] Clin Transl Oncol. 2006 Aug;8(8):611-5 [16952851.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):381-8; discussion 388-9 [7512326.001]
  • [Cites] Clin Transl Oncol. 2006 Mar;8(3):213-7 [16648122.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):27-39 [15621988.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1773-81 [15550582.001]
  • (PMID = 17652057.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  • [Number-of-references] 41
  •  go-up   go-down


25. Kim HO, Hwang SI, Yoo CH, Kim H: Preoperative colonoscopy for patients with gastric adenocarcinoma. J Gastroenterol Hepatol; 2009 Nov;24(11):1740-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative colonoscopy for patients with gastric adenocarcinoma.
  • BACKGROUND AND AIM: In patients with gastric adenocarcinoma (GA), the most common double primary cancer is colorectal cancer.
  • MATERIALS: Colonoscopy was carried out in 205 patients before gastric surgery for treatment of GA.
  • The prevalence of colorectal neoplasms (CRN, adenoma and adenocarcinoma) was evaluated according to age, sex, body mass index (BMI) and stage, location and differentiation of GA.
  • Synchronous adenoma and adenocarcinoma were detected in 68 (33.2%) and four (2.0%) patients, respectively.
  • All of the GA patients with synchronous colorectal adenocarcinoma were older than 50 years.
  • The stage, location and differentiation of GA and BMI did not show a significant difference in the incidence of CRN.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonoscopy. Colorectal Neoplasms / pathology. Gastrectomy. Mass Screening / methods. Neoplasms, Second Primary. Stomach Neoplasms / pathology


26. Song KY, Jung CK, Park WS, Park CH: Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol; 2009 May;39(5):290-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma.
  • OBJECTIVE: This study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in Stage III gastric adenocarcinoma.
  • METHODS: We performed immunohistochemical staining for survivin, p53 and Bax in formalin-fixed, paraffin-embedded blocks from 157 surgically resected Stage III gastric cancer tissues.
  • RESULTS: Of the 157 gastric cancer tissues, 63 (40.1%) cases showed positive expression for survivin protein.
  • Survivin and p53 were independent prognostic factors in Stage III gastric cancer.
  • CONCLUSIONS: Survivin protein is an important predictive and prognostic parameter of poor outcome in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Microtubule-Associated Proteins / genetics. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336448.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


27. Song SY, Son HJ, Kim MH, Nam ES, Rhee JC, Park C: Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology; 2007 Apr-May;54(75):973-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of maspin expression in human gastric adenocarcinoma.
  • However, molecular aspects in carcinogenesis and progression of gastric cancer remain largely unclear.
  • Previously we reported for the first time that maspin is induced in the course of gastric carcinogenesis.
  • In the present study we evaluated maspin induction in gastric adenocarcinoma in relation to a number of clinicopathologic feature.
  • METHODOLOGY: Maspin expression was examined by Western blot analysis and immunohistochemical staining in 82 cases of gastric adenocarcinoma.
  • RESULTS: In Western blot analysis, gastric specimens of tumor showed increased maspin expression compared with corresponding normal tissues in 54 of 82 patients (66%).
  • Tumor shows increased maspin expression compared with normal tissue in 81.1% of stage IV patients and 83.3% of N3 patients.
  • The frequency of maspin induction was associated with the stage of gastric cancer (p = 0.01) and lymph node metastasis (p = 0.03).
  • CONCLUSIONS: Our data suggest that maspin may have an important role in the progression and metastasis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Serpins / analysis. Serpins / metabolism. Stomach Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591106.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


28. Smith BR, Stabile BE: Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy. J Gastrointest Surg; 2007 Feb;11(2):127-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy.
  • National trends indicate a longstanding decline in gastric adenocarcinoma due presumably to a decreasing prevalence of Helicobacter pylori infection.
  • Nonetheless, surgical outcomes continue to include relatively high morbidity and mortality rates owing to the advanced stage of disease encountered.
  • We hypothesize that recent immigration patterns are responsible for a leveling off or even reversal of the declining incidence of gastric cancer associated with H. pylori infection.
  • A retrospective review of a consecutive case series at a public teaching hospital located in an area of high immigration was conducted that included all patients presenting, from 1995 through 2004, with gastric adenocarcinoma.
  • There was no decline in the frequency of gastric adenocarcinoma among the study population over the 10 years.
  • The operation rate decreased and the gastric resection rate increased from the early period to the recent period as fewer incurable advanced stage (M1) patients underwent exploratory laparotomy and were palliated by nonoperative means.
  • We conclude that in an area of high immigration there has been no decline in gastric adenocarcinoma rates over the past decade, and the marked reduction in perioperative mortality was due to near elimination of nontherapeutic laparotomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Laparotomy / mortality. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6220-32 [16135489.001]
  • [Cites] Br J Surg. 1988 Jul;75(7):708-12 [2458160.001]
  • [Cites] Gut. 2005 Nov;54(11):1541-5 [15955787.001]
  • [Cites] Am Surg. 2005 Sep;71(9):797-801 [16468522.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1260-2 [8983624.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):7-13 [3337564.001]
  • [Cites] Curr Probl Surg. 2005 Dec;42(12):796-862 [16344044.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S30-6 [7762737.001]
  • [Cites] Semin Oncol. 1996 Jun;23 (3):347-51 [8658218.001]
  • [Cites] Curr Probl Surg. 2005 Nov;42(11):756-89 [16310017.001]
  • [Cites] Gastrointest Endosc. 1994 Nov-Dec;40(6):694-9 [7859967.001]
  • [Cites] Endoscopy. 1992 Jun;24(5):424-7 [1505491.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4509-17 [16002841.001]
  • [Cites] Surgery. 1993 Jan;113(1):14-27 [8417483.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1169-79 [9609753.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12 ):1153-8 [9373284.001]
  • [Cites] Surg Endosc. 2001 Sep;15(9):1016-9 [11443448.001]
  • [Cites] Epidemiol Rev. 1986;8:1-27 [3533579.001]
  • [Cites] Semin Oncol. 1996 Jun;23 (3):336-46 [8658217.001]
  • [Cites] Pediatrics. 2001 Feb;107(2):373-80 [11158472.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 17390160.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Wang GQ, Wei WQ, Zhang JH: [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases]. Ai Zheng; 2007 Nov;26(11):1153-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases].
  • BACKGROUND & OBJECTIVE: The survival time of untreated advanced gastric cardiac adenocarcinoma patients is about 8-9 months.
  • This study was to observe the natural progression of untreated early stage gastric cardiac adenocarcinoma.
  • METHODS: In 1987, at a high risk area of esophageal cancer, 851 patients with a previous cytologic diagnosis of esophageal dysplasia were re-examined by endoscopy, and 43 of them were diagnosed histologically as gastric cardiac adenocarcinoma.
  • Of the 43 patients, 31 had early stage tumors, 12 had advanced tumors.
  • The 17 early stage patients who refused treatment were followed up for 14 years till death.
  • RESULTS: Of the 17 untreated patients, 12 were died of gastric cardiac adenocarcinoma, 5 were died of non-cancer diseases; 13 had survived for over 5 years.
  • CONCLUSIONS: The progression of early stage cardiac cancer to advanced cancer is a very slow and long process, which is very helpful for early diagnosis and choice of therapeutic timing.
  • The therapeutic effect on early stage cardiac cancer should be assessed with consideration of the natural history of this disease.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Disease Progression. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991310.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


30. Smith BR, Stabile BE: Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg; 2009 Jun;144(6):506-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young.
  • OBJECTIVE: To determine whether very young patients with gastric adenocarcinoma as compared with older patients with the disease have a biologically more aggressive form of the disease, presenting at an advanced stage and conferring unusually poor perioperative and long-term outcomes.
  • DESIGN, SETTING, AND PATIENTS: A 15-year, single-institution, retrospective review and analysis of demographic and outcomes data for 350 patients diagnosed with gastric adenocarcinoma.
  • MAIN OUTCOME MEASURES: Histologic features, frequency of stage IV disease, frequency of curative gastric resection, postoperative mortality, and long-term survival in very young and older patient groups.
  • Very young patients (aged < or = 35 years) as compared with older patients (aged > 35 years) more often had diffuse-type tumor histologic findings (93% vs 69%, respectively; P = .003), adjacent organ invasion (74% vs 29%, respectively; P = .001), nodal metastases (94% vs 70%, respectively; P = .046), distant metastases (81% vs 50%, respectively; P = .003), and stage IV disease (90% vs 64%, respectively; P = .007).
  • Very young patients as compared with older patients had high postoperative mortality (22% vs 2%, respectively; P = .003) related to advanced-stage disease.
  • CONCLUSIONS: Very young patients (aged < or = 35 years) with gastric adenocarcinoma have significantly higher incidences of diffuse-type tumor histologic findings and both locally advanced and metastatic disease at presentation.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528381.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Liu YH: [A prospective study of FOLFOX7 scheme as neoadjuvant chemotherapy for stage III gastric adenocarcinoma]. Zhonghua Wai Ke Za Zhi; 2009 Sep 1;47(17):1305-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A prospective study of FOLFOX7 scheme as neoadjuvant chemotherapy for stage III gastric adenocarcinoma].
  • OBJECTIVE: To evaluate the efficacy and safety of FOLFOX7 scheme as neoadjuvant chemotherapy in patients with stage III gastric adenocarcinoma.
  • METHODS: From May 2005 to May 2007, 27 patients with stage III gastric adenocarcinoma were given neoadjuvant chemotherapy with FOLFOX7 scheme.
  • The safety, objective response rate and pathological rate of neoadjuvant chemotherapy was assessed according to NCI-CTC v3.0, RECIST 2000, and the criteria established by Japanese Research Society for Gastric Cancer, respectively.
  • CONCLUSION: FOLFOX7 scheme as neoadjuvant chemotherapy for selected patients with stage III gastric adenocarcinoma can be well tolerated, it could induce tumor down-staging and improve R0 resection rate, although the long term efficacy remains to be evaluated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20092724.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


32. Oblak I, Velenik V, Anderluh F, Strojan P: Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia. Eur J Surg Oncol; 2007 Oct;33(8):982-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia.
  • AIMS: To analyze the results of postoperative concomitant radiochemotherapy with 5-florouracil (5-FU) and leucovorin (LV) in patients with gastric carcinoma treated in a single institution.
  • METHODS: During 2001-2004, 123 patients with the mean age of 60 years, were treated for adenocarcinoma of the stomach, stage Ib-IV, with postoperative concomitant radiochemotherapy.
  • In the multivariate analysis, the initial Hb level was identified as independent prognostic factor for all survival four endpoints, the involvement of whole stomach with cancer for LRC, the total dose of 5-FU per five-day cycle for DFS, and pT stage for DSS.
  • CONCLUSIONS: In operable gastric carcinoma, postoperative concomitant radiochemotherapy with 5-FU and LV is feasible and its toxicity acceptable.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258881.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Wei YC, Zhou FL, He DL, Bai JR, Ding H, Wang XY, Nan KJ: Oxidative stress in depressive patients with gastric adenocarcinoma. Int J Neuropsychopharmacol; 2009 Sep;12(8):1089-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress in depressive patients with gastric adenocarcinoma.
  • The present study was designed to investigate oxidative stress status in depressive patients with gastric adenocarcinoma (GA) at TNM stage III.

  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19272208.001).
  • [ISSN] 1469-5111
  • [Journal-full-title] The international journal of neuropsychopharmacology
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 4Y8F71G49Q / Malondialdehyde; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


34. Lee KY, Jap A, Cheah E, Looi A: Orbital metastatic tumour as initial manifestation of asymptomatic gastric adenocarcinoma. Ann Acad Med Singapore; 2006 Oct;35(10):719-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastatic tumour as initial manifestation of asymptomatic gastric adenocarcinoma.
  • INTRODUCTION: Metastatic orbital tumour from gastric cancer is rare.
  • CLINICAL PICTURE: We report a case, with clinicopathological correlation, of metastatic gastric adenocarcinoma presenting first in the orbit with diplopia.
  • TREATMENT AND RESULTS: Excisional biopsy was performed and histopathology confirmed a metastatic adenocarcinoma.
  • Focused gastrointestinal screening revealed an otherwise asymptomatic Stage IV gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102896.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


35. Euanorasetr C, Lertsithichai P: Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy. Gastric Cancer; 2007;10(1):18-23
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy.
  • BACKGROUND: The aim of the present study was to determine the prognostic significance of peritoneal washing cytology (PWC) among Thai patients with gastric adenocarcinoma.
  • METHODS: Medical charts of 97 patients with gastric adenocarcinoma who underwent curative D2 gastrectomy between October 1995 and September 2005 were reviewed.
  • Factors significantly associated with positive PWC included tumor location, macroscopic findings, histology, depth of tumor invasion, nodal involvement, TNM stage, and angiolymphatic invasion.
  • CONCLUSION: Gastric adenocarcinoma with positive PWC should be considered stage IV disease.
  • PWC should be included in the staging of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Neoplasms / pathology. Peritoneum / cytology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Gastric Cancer. 2001;4(1):27-33 [11706624.001]
  • [Cites] Surg Gynecol Obstet. 1961 Apr;112:469-74 [13772295.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):71-5 [9808508.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7374-7 [16437646.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):170-6, discussion 176-7 [16455447.001]
  • [Cites] Surg Today. 1999;29(2):111-5 [10030734.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):611-7 [9179118.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):347-53 [15915368.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] Surg Today. 2005;35(11):919-24 [16249844.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):92-100 [10813130.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):44-7 [2049751.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):1-7 [11957063.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Surg Oncol. 1992 Oct;1(5):341-6 [1341269.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):372-9 [9527060.001]
  • [Cites] Acta Cytol. 1978 Jul-Aug;22(4):225-9 [281825.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17(2):103-7 [10449681.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):520-4 [10027323.001]
  • [Cites] World J Surg. 2005 Sep;29(9):1131-4 [16086213.001]
  • [Cites] Cancer. 1979 Oct;44(4):1476-80 [498022.001]
  • [Cites] Gastric Cancer. 2005;8(4):228-37 [16328597.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):629-31 [1347336.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):339-41 [15843872.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5 [10518099.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1419-23 [14532985.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):226-9 [7630168.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):411-5 [9718170.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):133-7; discussion 137 [7740800.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):450-4; discussion 455 [7639005.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):437-42 [2160771.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • (PMID = 17334713.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Joo M, Kim H, Kim MK, Yu HJ, Kim JP: Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol; 2005 Jul;20(7):1039-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma.
  • However, the expression and distribution of Ep-CAM in gastric premalignant and malignant lesions are not well known.
  • METHOD: We examined the expression of Ep-CAM in 99 cases of gastric adenocarcinoma and associated uninvolved gastric mucosa, 39 cases of gastric biopsy specimens with chronic gastritis (CG) with or without intestinal metaplasia (IM) (25 cases) and gastric epithelial dysplasia (GED) (14 cases) by immunohistochemical staining.
  • In gastric adenocarcinoma, we correlated the results with established prognostic factors, and in IM and GED, with Hepatocyte paraffin 1 (Hep Par 1) expression, introduced as a marker of IM.
  • RESULTS: Ep-CAM overexpression was noted in 0% of normal epithelia, 93.9% of IM, 42.9% of GED and 34.3% of adenocarcinoma.
  • The average immunostaining score of normal epithelia, IM, GED and gastric adenocarcinoma was 0.14 (+/- 0.26), 7.18 (+/- 1.93), 5.67 (+/- 2.29) and 4.09 (+/- 1.89), respectively.
  • Ep-CAM overexpression in adenocarcinoma correlated with Lauren classification and histologic grade, but not with tumor stage, lymph node metastasis and p53 expression.
  • CONCLUSION: Our findings suggest that increased levels of Ep-CAM represent an early event in gastric carcinogenesis, and seem to have a specific relation with the development of IM as a morphoregulatory molecule.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Gastric Mucosa / metabolism. Intestines / pathology. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955212.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human
  •  go-up   go-down


37. Lee SW, Kang SB, Kim YS, Nam SW, Lee DS, Lee HK, Han SW: [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2007 Mar;49(3):152-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical overexpression of c-erbB-2 and c-met proteins according to the histopathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in gastric adenoma and gastric adenocarcinoma.
  • In adenocarcinoma, c-met expression was significantly related with lymph node metastasis.
  • CONCLUSIONS: c-erbB-2 would be involved in the development of relatively early stage gastric carcinogenesis. c-erbB-2 is related with histologic type and c-met with lymph node metastasis in gastric carcinomas.
  • Although meaning for the expression of these proteins in gastric carcinomas would be different, these proteins may play as important oncogenes in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-met / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172343.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


38. Kravtsov VG, Shakhmurov MG, Sukmanov OV, Zaĭrat'iants OV, Shirin NI: [Expression of cycline-dependent kinase p27 in the low differentiated gastric adenocarcinoma]. Arkh Patol; 2006 Sep-Oct;68(5):14-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of cycline-dependent kinase p27 in the low differentiated gastric adenocarcinoma].
  • The authors investigated p27 expression in 21 cases of high-grade gastric adenocarcinoma with portions of signet ring cell differentiation, by comparing that in 11 cases of chronic atrophic gastritis with Helicobacter pylori and in 5 cases of the intact gastric mucosa.
  • The mean age of patients with gastric adenocarcinoma was 67.7 years (35-86 years); there were 9 males and 12 females.
  • All tumors were of T3 N1-2 M0 stage.
  • The investigations indicated a great difference (by 2.4-7.6 times) and a statistically significant decrease in p27 expression in the adenocarcinoma cells as compared to the comparison groups.
  • However, there was no significant correlation between the lower level of p27 expression and the prognosis in patients with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chronic Disease. Female. Gastric Mucosa / metabolism. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Gastritis, Atrophic / metabolism. Gastritis, Atrophic / microbiology. Gastritis, Atrophic / pathology. Helicobacter Infections / microbiology. Helicobacter pylori / metabolism. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144523.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


39. Lee DS, Kang SB, Baek JT, Nam SW, Lee KM, Ahn BM, Lee EH, Han SW, Chung IS: [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2005 Jun;45(6):394-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical expression of bcl-2, bcl-xL, bax, and p53 proteins according to the pathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in the gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal bcl-2, bcl-xL, bax, p53 antibodies were performed on paraffin embedded specimens from forty-one gastric adenomas and 100 gastric adenocarcinomas.
  • In the adenocarcinoma, the bax expression was significantly related with the depth of invasion, lymph node metastasis, and TNM stage.
  • CONCLUSIONS: Bcl-2 protein would be related with the development of gastric adenoma, especially with high grade dysplasia.
  • Bcl-xL and p53 proteins would be involved in the development of relatively early stage of gastric adenocarcinoma but not in tumor progression.
  • Bax protein would be involved in the development of gastric adenocarcinoma and related with depth of invasion, lymph node metastasis, and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973073.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


40. Zhao P, Liu W, Lu YL: Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients. World J Gastroenterol; 2005 Sep 28;11(36):5735-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.
  • AIM: To investigate the expression of fragile histidine triad (FHIT) protein, and the possible relationship between FHIT expression and clinicopathological indices in gastric carcinoma.
  • METHODS: FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis.
  • RESULTS: The FHIT protein expression was positive in 28/76 (36.8%) cases of adenocarcinoma tissue, 22/58 (37.9%) cases of adjacent dysplastic tissue and 76/76 (100%) cases of distal normal gastric mucosa.
  • There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa (P = 0.000).
  • The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer.
  • Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma.
  • [MeSH-major] Acid Anhydride Hydrolases / metabolism. Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237777.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4481500
  •  go-up   go-down


41. Takamori H, Kanemitsu K, Tsuji T, Kusano S, Chikamoto A, Okuma T, Iyama K: Metastatic gastric tumor secondary to pancreatic adenocarcinoma. J Gastroenterol; 2005 Feb;40(2):209-12
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic gastric tumor secondary to pancreatic adenocarcinoma.
  • We report a patient who suffered from gastric metastasis secondary to pancreatic adenocarcinoma 1 year after pancreatectomy.
  • The histological diagnosis was well-differentiated adenocarcinoma of the pancreas, stage IIB; T1N1M0.
  • One month later, she complained of epigastric pain and underwent gastric endoscopy, which revealed a submucosal tumor in the fornix posterior wall.
  • Histological diagnosis of the biopsy specimen was well-differentiated adenocarcinoma, and immunohistochemical studies, using anti-cytokeratin 7 and -20 monoclonal antibodies, were compatible with gastric metastasis from pancreatic carcinoma.
  • A F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) scan revealed a high-uptake lesion, which coincided with the gastric tumor.
  • Histopatholoical examination of the resected specimen revealed submucosal growth of the metastatic cancer (well-differentiated adenocarcinoma).
  • [MeSH-major] Adenocarcinoma / secondary. Pancreatic Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] CA-19-9 Antigen / blood. Female. Gastric Mucosa / pathology. Gastroscopy. Humans. Immunohistochemistry. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770407.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


42. Bani-Hani KE: Clinicopathological comparison between young and old age patients with gastric adenocarcinoma. Int J Gastrointest Cancer; 2005;35(1):43-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological comparison between young and old age patients with gastric adenocarcinoma.
  • BACKGROUND: There are controversies regarding the differences in the clinicopathological characteristics of gastric cancer between young and older patients.
  • PATIENTS AND METHODS: Records of all Jordanian patients with gastric adenocarcinoma managed at our hospitals between 1991 and 2001 were reviewed.
  • RESULTS: In the young group, in comparison with older group, females were more predominant (p=0.049), family history of gastric cancer was more common (p=0.006), proximal location and involvement of the entire stomach were more (p<0.001), and diffuse cancers (65% vs 13%) and poorly differentiated carcinomas (47% vs 26%) were more prevalent.
  • Advanced tumor stage was the same in both groups (65% vs 64%, ns).
  • However, age was significantly associated with survival when treated as a continuous variable even after adjusting for the effects of site and stage of tumor on survival.
  • CONCLUSIONS: Special features of gastric cancer differ significantly between young and older age groups.
  • Greater awareness of early-onset gastric cancer is mandatory for detecting cancer early enough so that it is treated successfully.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2690-3 [10522066.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1904-9 [11419427.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1362-5 [3815307.001]
  • [Cites] Int J Mol Med. 2000 Feb;5(2):185-90 [10639599.001]
  • [Cites] Endoscopy. 2003 Jan;35(1):61-7 [12510228.001]
  • [Cites] Public Health. 2002 Jan;116(1):39-44 [11896635.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2506-11 [10375095.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):993-9 [10551330.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):22-6 [9915238.001]
  • [Cites] Scand J Gastroenterol. 2000 Mar;35(3):255-9 [10766317.001]
  • [Cites] Histopathology. 2003 Feb;42(2):128-36 [12558744.001]
  • [Cites] Zentralbl Chir. 2002 Apr;127(4):270-4 [12085274.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2174-8 [15259060.001]
  • [Cites] Br J Surg. 1985 Apr;72(4):289-91 [3986480.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):45-8 [8554035.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1999 Mar;37(3):154-6 [11829807.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1552-5 [11813570.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Oct;14 Suppl 3:48-54 [11050487.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Nov;87(1):13-22 [10579611.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):233-7 [10782897.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):633-6 [11295093.001]
  • [Cites] Ann Surg Oncol. 2000 Jun;7(5):346-51 [10864341.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):207-10 [11040944.001]
  • [Cites] Histopathology. 2000 Aug;37(2):124-30 [10931235.001]
  • [Cites] Med J Malaysia. 2000 Mar;55(1):135-7 [11072499.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):214-9 [10440758.001]
  • [Cites] Am J Surg. 1996 Nov;172(5):473-6; discussion 476-7 [8942547.001]
  • [Cites] Hepatogastroenterology. 1996 Sep-Oct;43(11):1273-80 [8908562.001]
  • [Cites] Rev Gastroenterol Mex. 1999 Apr-Jun;64(2):75-7 [10532131.001]
  • [Cites] Rev Gastroenterol Peru. 2000 Oct-Dec;20(4):384-394 [12140573.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1997 May;35(5):271-3 [10374558.001]
  • [Cites] Postgrad Med J. 1999 Jan;75(879):22-6 [10396582.001]
  • [Cites] Aust N Z J Surg. 1999 Jun;69(6):443-6 [10392889.001]
  • [Cites] Surgery. 2001 Oct;130(4):612-7; discussion 617-9 [11602891.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1999 May;21(3):224-6 [11776843.001]
  • (PMID = 15722573.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Bektas S, Bahadir B, Ucan BH, Ozdamar SO: CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance. Pathol Oncol Res; 2010 Dec;16(4):569-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.
  • CD24 and galectin-1 expression in gastric adenocarcinoma and their clinicopathologic significance remained largely unknown.
  • We aimed to evaluate expressions and staining intensities of CD24 and galectin-1 in gastric adenocarcinoma and to investigate the interrelation with clinicopathologic parameters including survival.
  • 93 cases with gastric adenocarcinoma were reevaluated histopathologically and immunohistochemistry was performed with antibodies against CD24 and galectin-1.
  • CD24 staining intensity was associated with lymphovascular invasion (p = 0.007), serosal invasion (p = 0.001), stage (p = 0.001) and lymph node metastasis (p = 0.005).
  • Galectin-1 staining intensity in tumor-associated stromal cells was associated with tumor location (p = 0.031), lymphovascular invasion (p = 0.001), perineural invasion (p = 0.001), serosal invasion (p = 0.001), differentiation (p = 0.003), stage (p = 0.001) and lymph node metastasis (p = 0.001).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antigens, CD24 / biosynthesis. Galectin 1 / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2006;202(8):569-76 [16828238.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1849-58 [12673710.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):125-33 [19072375.001]
  • [Cites] Blood. 1997 May 1;89(9):3385-95 [9129046.001]
  • [Cites] Glycobiology. 2006 Nov;16(11):137R-157R [16840800.001]
  • [Cites] Pathol Res Pract. 2009;205(8):524-33 [19243896.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):183-92 [14716744.001]
  • [Cites] Glycoconj J. 2004;19(7-9):537-42 [14758077.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):171-5 [7622305.001]
  • [Cites] Angiogenesis. 1999;3(4):317-25 [14517411.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8932-41 [16219933.001]
  • [Cites] Cell Mol Life Sci. 2007 May;64(10):1254-8 [17364145.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):587-94 [18288388.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Urology. 2008 Sep;72(3):603-7 [18384848.001]
  • [Cites] Histol Histopathol. 2009 Mar;24(3):309-16 [19130400.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):302-10 [11274640.001]
  • [Cites] Pathol Oncol Res. 2009 Jun;15(2):279-83 [18752058.001]
  • [Cites] Glycoconj J. 2004;19(7-9):507-15 [14758074.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):1083-9 [15477346.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10783-93 [16322224.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S351-4 [16507407.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1215-21 [12368195.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):231-6 [12610508.001]
  • [Cites] Glia. 2001 Mar 1;33(3):241-55 [11241742.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 Sep;27(9):1331-4 [17884770.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4906-13 [14581365.001]
  • [Cites] Cancer Lett. 1999 Aug 23;143(1):87-94 [10465342.001]
  • [Cites] Dev Dyn. 2007 Apr;236(4):1014-24 [17366633.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):545-53 [18202194.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2748-58 [17680316.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):370-9 [12471620.001]
  • [Cites] J Gastrointest Surg. 2007 Apr;11(4):445-51 [17436128.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1058-67 [9028339.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2331-8 [17304502.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4717-21 [7553654.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6574-81 [16166435.001]
  • [Cites] J Cell Biol. 1990 May;110(5):1681-91 [2335567.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):377-86 [12649338.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):39-43 [9988230.001]
  • [Cites] J Histochem Cytochem. 2001 Apr;49(4):539-49 [11259457.001]
  • [Cites] BMC Cancer. 2008 Apr 24;8:118 [18433506.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):506-14 [19050962.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):255-62 [15339045.001]
  • [Cites] J Pathol. 2001 Jan;193(1):80-7 [11169519.001]
  • (PMID = 20177845.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / CD24 protein, human; 0 / Galectin 1
  •  go-up   go-down


44. Friedrich-Rust M, Jaeger C, Gossner L, May A, Günter E, Stolte M, Ell C: [Early duodenal adenocarcinoma arising in gastric metaplasia treated by endoscopic resection]. Z Gastroenterol; 2006 Apr;44(4):323-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early duodenal adenocarcinoma arising in gastric metaplasia treated by endoscopic resection].
  • Most duodenal carcinomas are diagnosed at a more advanced stage.
  • This report describes the case of a 59-year-old lady with an early duodenal adenocarcinoma diagnosed at check-up gastroduodenoscopy in an outpatient clinic who was referred to us for further investigation and management.
  • Histopathological examination revealed the rare entity of an early duodenal carcinoma arising from incomplete-type gastric metaplasia in the duodenum.
  • In summary, the presented paper describes a case of successful endoscopic treatment of an early duodenal carcinoma arising from incomplete gastric metaplasia.
  • [MeSH-major] Adenocarcinoma / surgery. Duodenal Neoplasms / surgery. Endoscopy, Gastrointestinal. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625461.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Wilson D, Hiller L, Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol); 2005 Apr;17(2):81-90
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of second-line chemotherapy for advanced gastric adenocarcinoma.
  • Palliative chemotherapy has been shown to improve survival compared with best supportive care alone in patients with unresectable or recurrent gastric cancer.
  • At this stage, no standard second-line chemotherapy can be offered.
  • We review the published data concerning the use of second-line chemotherapy in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Salvage Therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830569.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


46. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH: Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer; 2005 Jun 1;103(11):2383-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
  • BACKGROUND: Positron emission tomography (PET) with 18- fluorodeoxyglucose (FDG) has been used to both detect and stage a variety of malignancies.
  • The current study examined the value of PET for preoperative staging of gastric adenocarcinoma.
  • METHODS: Sixty-eight patients (49 males and 19 females) with gastric adenocarcinoma, who were referred for preoperative FDG-PET scans, were enrolled in this study.
  • RESULTS: For the primary tumor of a gastric adenocarcinoma, PET demonstrated an increased uptake in 64 of 68 patients (sensitivity, 94%), with a mean SUV of 7.0 (range, 0.9-27.7).
  • A comparison of FDG uptake and clinicopathologic features showed significant association between FDG uptake and macroscopic type, tumor size, lymph node metastasis, histologic type, and TNM stage.
  • CONCLUSIONS: FDG-PET improves the preoperative TNM staging of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Stomach Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856477.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Li M, Jin Y, Sun WJ, Yu Y, Bai J, Tong DD, Qi JP, Du JR, Geng JS, Huang Q, Huang XY, Huang Y, Han FF, Meng XN, Rosales JL, Lee KY, Fu SB: Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol; 2009 Sep;219(1):87-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma.
  • The goal of the present study was to investigate whether the expression and alternative splicing of ING4 transcripts are involved in the initiation and progression of stomach adenocarcinoma.
  • ING4 mRNA and protein expression was examined in gastric adenocarcinoma tissues and human gastric adenocarcinoma cell lines by RT-PCR, real-time RT-PCR, tissue microarray immunohistochemistry, and western blot analysis.
  • Our data showed that ING4 mRNA and protein were dramatically reduced in stomach adenocarcinoma cell lines and tissues, and significantly less in female than in male patients.
  • We also found that reduced ING4 mRNA expression correlated with the stage of the tumour.
  • These variants cause a codon frame-shift and, eventually, deletion of the NLS or PHD domain contributing to the mislocalization of p53 and/or HAT/HDAC complexes and, subsequently, altered gene expression in gastric adenocarcinoma.
  • These results suggest that attenuated and aberrant ING4 expression may be involved in the initiation and progression of stomach adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):129-35 [11804739.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):23-30 [17956589.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3162-70 [12130582.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2373-8 [12750254.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Oct;87(1):57-63 [14630091.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):328-32 [15029197.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16251-6 [15528276.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):1032-8 [15882981.001]
  • [Cites] Gene. 2005 Aug 15;356:109-17 [15935570.001]
  • [Cites] Mol Cell. 2006 Jan 6;21(1):51-64 [16387653.001]
  • [Cites] Exp Cell Res. 2006 Apr 15;312(7):951-61 [16516887.001]
  • [Cites] J Cell Sci. 2006 Jul 1;119(Pt 13):2635-41 [16787944.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):633-49 [16997150.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34677-86 [16973615.001]
  • [Cites] Genomics. 2006 Dec;88(6):855-64 [16920330.001]
  • [Cites] Oncogene. 2007 Aug 9;26(36):5247-57 [17325660.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • (PMID = 19479822.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] None / None / / 82788-1; Canada / Canadian Institutes of Health Research / / 82788-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Homeodomain Proteins; 0 / ING4 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ CAMS3767; NLM/ PMC3855470
  •  go-up   go-down


48. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Iacobuzio-Donahue C, Ashfaq R, Kern SE, Maitra A, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Montgomery E, Schulick RD: MKK4 status predicts survival after resection of gastric adenocarcinoma. Arch Surg; 2006 Nov;141(11):1095-9; discussion 1100
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MKK4 status predicts survival after resection of gastric adenocarcinoma.
  • HYPOTHESIS: Lack of expression of the tumor-suppressor gene MKK4 is significantly correlated with poor survival after resection of gastric adenocarcinoma.
  • PATIENTS: Patients operated on because of gastric adenocarcinoma between 1983 and 1995.
  • Given the small size (7%) of the MKK4-negative group (as expected, given the 5%-10% incidence of genetic loss in carcinomas), a Cox proportional hazards analysis was performed, adjusting for age, sex, and tumor stage.
  • CONCLUSIONS: The lack of expression of the tumor-suppressor gene MKK4 in resected gastric adenocarcinoma is robustly associated with poor survival.
  • This finding may provide a useful prognostic tool in patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. MAP Kinase Kinase 4 / genetics. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116802.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.12.2 / MAP Kinase Kinase 4
  •  go-up   go-down


49. Ye S, Rong J, Lin TY, Xiao J, Huang Y, Zhai LZ: [FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug;28(9):1599-602
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma].
  • OBJECTIVE: To compare the efficacy and tolerability of the regimen FOLFOX [1eucovorin (LV), 5-fluorouracil (5-Fu) and oxaliplatin] and the regimen PLF (Paclitaxel, leucovorin and 5-Fu) for treatment of advanced gastric adenocarcinoma.
  • METHODS: We retrospectively studied the clinical data of 132 patients with stage IV gastric adenocarcinoma treated by FOLFOX (group A, n=60) or PLF (group B, n=72).
  • CONCLUSION: Both FOLFOX and PLF can serve as effective first-line treatment of stage IV gastric adenocarcinoma with good tolerance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819876.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; P88XT4IS4D / Paclitaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


50. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Choi WH, Choi SH, Wang LB, Noh SH: Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol; 2008 May;15(5):1464-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection.
  • BACKGROUND: Conflicting results from previous studies on gastric adenocarcinoma (GC) in young patients have led to controversy surrounding the prognosis for young GC patients.
  • However, in regard to T4 invasion, N3 lymph node metastasis, and TNM stage IV, the characteristics of the tumors of young patients were similar to those of middle-aged and elderly patients.
  • Stratified by TNM stage, young patients showed better overall survival at stage I than middle-aged patients, and at stages I, II, and IIIa than elderly patients.
  • Young patients could gain a survival benefit after curative resection with stage I disease.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340495.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Fujita T, Katai H, Morita S, Saka M, Fukagawa T, Sano T: Short-term outcomes of Roux-en-Y stapled anastomosis after distal gastrectomy for gastric adenocarcinoma. J Gastrointest Surg; 2010 Feb;14(2):289-94
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term outcomes of Roux-en-Y stapled anastomosis after distal gastrectomy for gastric adenocarcinoma.
  • METHODS: We evaluated the data of 701 consecutive patients of gastric adenocarcinoma who underwent conventional open distal gastrectomy with Roux-en-Y reconstruction.
  • The data collected included details on the method used for the Roux-en-Y reconstruction, the disease stage, extent of lymph node dissection, performance rate of truncal vagotomy, operation time, operative blood loss, length of hospital stay, and postoperative complications.
  • Postoperatively, delayed gastric emptying occurred in 14 (1.9%) patients, including seven (4.2%) from the MS group and seven (1.3%) from the HS group (p = 0.038).
  • CONCLUSION: There were no significant disadvantages of employing mechanical stapling for anastomosis, except for the high rate of delayed gastric emptying.
  • More consideration therefore needs to be given to decreasing the frequency of gastric emptying disturbance post surgery using mechanical staples.
  • [MeSH-major] Adenocarcinoma / surgery. Anastomosis, Roux-en-Y / methods. Gastric Bypass / methods. Stomach Neoplasms / surgery. Surgical Stapling
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastric Emptying. Humans. Male. Middle Aged. Retrospective Studies. Suture Techniques. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1996 Jul;172(1):24-8 [8686797.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):900-4 [3664221.001]
  • [Cites] Int J Clin Oncol. 2007 Dec;12(6):433-9 [18071862.001]
  • [Cites] Am J Surg. 1981 Jan;141(1):143-7 [7006425.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):603-5 [3896372.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):50-2 [2405935.001]
  • [Cites] Am J Surg. 1980 Jan;139(1):147-52 [6985775.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):305-9 [15783056.001]
  • [Cites] Arch Surg. 1975 Sep;110(9):1079-82 [1098615.001]
  • [Cites] Br J Surg. 1986 May;73(5):345-8 [3518855.001]
  • [Cites] Am J Surg. 1988 Mar;155(3):490-4 [3344916.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):337-41 [2021851.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):456-60 [3510704.001]
  • [Cites] Adv Surg. 1994;27:233-55 [8140975.001]
  • [Cites] World J Surg. 2002 Dec;26(12):1452-7 [12370787.001]
  • [Cites] Ann Surg. 1984 May;199(5):590-7 [6721608.001]
  • [Cites] Gastric Cancer. 2004;7(1):24-30 [15052436.001]
  • [Cites] Surg Today. 2007;37(2):122-6 [17243030.001]
  • [Cites] Am J Surg. 1989 Mar;157(3):282-6 [2919731.001]
  • [Cites] Br J Surg. 1982 Dec;69(12):722-4 [6756537.001]
  • (PMID = 19904576.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Graziosi L, Bugiantella W, Gunnellini M, Qweider NA, Cavazzoni E, Donini A: [Preliminary experience in treatment of locally advanced gastric adenocarcinoma with peri-operative chemotherapy]. G Chir; 2010 Apr;31(4):147-50
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary experience in treatment of locally advanced gastric adenocarcinoma with peri-operative chemotherapy].
  • AIM: Gastric Cancer (GC) is a poor prognosis neoplasm and it is often diagnosed at advanced stage.
  • PATIENTS AND METHODS: Since November 2006, six patients with gastric adenocarcinoma, diagnosed by endoscopy, endoscopic ultrasonography and total body 18FDG-PET-CT, were enrolled in a program of peri-operative chemotherapy, according to the following inclusion criteria: cT2N+M0 or cT3-4NxM0, age < 75 years, Karnofsky Performance Status > 60%, absence of hepatic, renal and bone marrow failures.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444330.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Saletti P, Berthold D, Ghielmini M, Zucca E, Fazio N, Goldhirsch A, Cavalli F: Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma. Hepatogastroenterology; 2007 Apr-May;54(75):969-72
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma.
  • BACKGROUND/AIMS: ECF is an active regimen in advanced gastric adenocarcinoma (GAC).
  • Their median age was 59 years (range 32-74) and UICC stage was III-IV in 28 patients (59%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591105.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  •  go-up   go-down


54. Cidón EU, Cuenca IJ: Gastric Adenocarcinoma: Is Computed Tomography (CT) Useful in Preoperative Staging? Clin Med Oncol; 2009;3:91-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Adenocarcinoma: Is Computed Tomography (CT) Useful in Preoperative Staging?
  • BACKGROUND AND PURPOSE: Although multiple studies testing the accuracy of CT in the preoperative staging of gastric adenocarcinoma have been carried out, their results are controversial.
  • Whilst some authors claim that CT is an accurate method for preoperatively staging gastric cancer, others have advocated the contrary.
  • Because of this discrepancy we have retrospectively reviewed preoperative CT findings compared with histopathological results in patients with gastric adenocarcinoma.
  • PATIENTS AND METHODS: Seventy-two patients diagnosed with gastric cancer who underwent potentially curative surgery and preoperative staging CT of quality were included in the study.
  • The size, gastric wall thickening, presence of lymphadenopathy, adjacent organ invasion and location of the gastric mass was recorded.
  • CT staging was correlated with the final histopathological stage (TNM).
  • CONCLUSION: Spiral CT is not an accurate method in predicting preoperative stages in gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1997 Sep;41(3):314-9 [9378384.001]
  • [Cites] Br J Surg. 1989 Jun;76(6):535-40 [2758258.001]
  • [Cites] Tani Girisim Radyol. 2003 Sep;9(3):345-53 [14661602.001]
  • [Cites] Radiology. 1989 Nov;173(2):411-7 [2678255.001]
  • [Cites] Radiology. 1991 Nov;181(2):426-32 [1924784.001]
  • [Cites] Radiology. 1988 May;167(2):335-40 [3357941.001]
  • [Cites] Arch Surg. 1986 May;121(5):603-6 [3707336.001]
  • [Cites] Eur J Radiol. 1986 Aug;6(3):181-6 [3769940.001]
  • [Cites] Br J Surg. 1985 Mar;72(3):249-50 [3978390.001]
  • [Cites] Acta Chir Scand. 1985;151(6):571-3 [4090881.001]
  • [Cites] Ann R Coll Surg Engl. 1974 May;54(5):219-28 [4275295.001]
  • [Cites] Gastrointest Radiol. 1983;8(4):307-13 [6642146.001]
  • [Cites] Gastroenterology. 1981 Jan;80(1):45-50 [6778759.001]
  • [Cites] Radiology. 1995 Dec;197(3):705-11 [7480743.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):501-8 [7676691.001]
  • [Cites] Clin Ter. 1995 Dec;146(12):825-41 [8681503.001]
  • [Cites] Abdom Imaging. 2005 Jul-Aug;30(4):465-72 [15785907.001]
  • [Cites] AJR Am J Roentgenol. 2009 Apr;192(4):902-8 [19304693.001]
  • [Cites] Eur J Radiol. 2002 Feb;41(2):161-7 [11809546.001]
  • (PMID = 20689615.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2872601
  • [Keywords] NOTNLM ; computed tomography, (CT) / gastric adenocarcinoma / preoperative staging
  •  go-up   go-down


55. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B: Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest; 2009 May;27(4):459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
  • In this work, the promoter methylation status of the RASSF1A in 92 gastric cardia adenocarcinoma (GCA) and corresponding normal tissues were investigated using Methylation-specific PCR (MSP) approach, immunohistochemistry method and RT-PCR were used respectively to examine the protein expression and mRNA expression of RASSF1A in tumors and corresponding normal tissues.
  • Methylation frequencies of stage III and IV tumor tissues were significantly higher than that in stage I and II tumor tissues (p <.05).
  • [MeSH-major] Adenocarcinoma / genetics. Cardia / chemistry. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160099.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


56. Fu S, Lu JJ, Zhang Q, Yang Z, Peng L, Xiong F: Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1488-94
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma.
  • PURPOSE: To evaluate the efficacy of intraoperative radiotherapy (IORT) followed by concurrent chemotherapy and external beam RT (EBRT) in the treatment of locally advanced gastric adenocarcinoma.
  • METHODS AND MATERIALS: A total of 97 consecutive and nonselected patients with newly diagnosed Stage T3, T4, or N+ adenocarcinoma of the stomach underwent gastrectomy with D2 lymph node dissection between March 2003 and October 2005.
  • CONCLUSIONS: Radical gastrectomy with D2 lymph node dissection and IORT followed by adjuvant chemoradiotherapy appeared to be feasible and well-tolerated in the treatment of locally advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Radiotherapy / methods. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538489.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Kunisaki C, Makino H, Kimura J, Takagawa R, Kosaka T, Ono HA, Akiyama H, Fukushima T, Nagahori Y, Takahashi M: Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery; 2010 Feb;147(2):204-11
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymphovascular invasion in patients with stage I gastric cancer.
  • BACKGROUND: Patients with stage I gastric cancer often suffer from tumor recurrence despite a generally favorable operative outcome.
  • METHODS: Between April 1985 and March 2000, a total of 1,880 patients with histologically proven stage I gastric cancer were included in this study.
  • RESULTS: Multivariate analysis in patients with all stage I gastric cancer revealed that depth of invasion, lymph node metastasis, and lymphovascular invasion independently influenced prognosis.
  • Moreover, advanced age was selected as an independent prognostic factor in patients with stage IA, and lymphovascular invasion in patients with stage IB gastric cancer by multivariate analyses.
  • The 5-year survival rates in stage T1N1 patients with moderate to severe lymphovascular invasion, T2N0 with moderate to severe lymphovascular invasion, and II were 95.1%, 83.5%, and 76.9%, respectively.
  • There was a significant difference in survival time between stage T1N1 and II (P = .0189) but not between stage T1N1 and T2N0 or stage T2N0 and II.
  • CONCLUSION: T2N0 gastric cancer patients with moderate to severe lymphovascular invasion may be suitable candidates for adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 19878963.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z: Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res; 2009 Sep 28;14(10):453-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma.
  • The aim of this study was to investigate the promoter methylation and expression of E-cadherin gene in gastric cardiac adenocarcinoma (GCA).
  • Methylation frequencies of stage III and IV tumor tissues was significantly higher than that in stage I and II tumor tissues (P = 0.01).
  • Positive immunostaining of stage III and IV tumor tissues was significantly lower than stage I and II tumor tissues (P<0.01).
  • CONCLUSIONS: High methylation status of the 5' CpG island of E-cadherin gene may be one of the mechanisms in the development of gastric cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Cardia. CpG Islands. DNA Methylation. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):869-76 [10023662.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Lancet. 1999 Jul 31;354(9176):356-7 [10437861.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(4):1-17 [14987388.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):376-9 [7841055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):355-9 [9139867.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • (PMID = 19748854.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3352230
  •  go-up   go-down


59. Ribeiro U Jr, Jorge UM, Safatle-Ribeiro AV, Yagi OK, Scapulatempo C, Perez RO, Corbett CE, Alves VA, Zilberstein B, Gama-Rodrigues J: Clinicopathologic and immunohistochemistry characterization of synchronous multiple primary gastric adenocarcinoma. J Gastrointest Surg; 2007 Mar;11(3):233-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemistry characterization of synchronous multiple primary gastric adenocarcinoma.
  • The aim of this investigation was to evaluate clinicopathologic and immunohistochemical characteristics of synchronous primary gastric adenocarcinomas.
  • Synchronous primary gastric adenocarcinomas were detected in 19/553 (3.43%) of the patients.
  • Synchronous neoplasias were diagnosed in earlier stage than solitary neoplasias, T1-T2 = 60.9% vs T1-T2 = 28.4%, p = 0.0001; and N0 = 68.4% vs N0 = 26.2%, p = 0.001. p53 was detected in 52.6% of the patients with synchronous tumors.
  • Synchronous gastric adenocarcinomas presented higher frequency of intestinal type and early gastric cancer in comparison to solitary gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):239-42 [7657386.001]
  • [Cites] Surg Today. 1993;23(2):186-8 [8467167.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2004 Oct;59(5):279-85 [15543400.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4662-5 [8840981.001]
  • [Cites] Mod Pathol. 1999 Jan;12(1):15-20 [9950157.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):7-18 [9655287.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):200-3 [10861474.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1523-30 [11813565.001]
  • [Cites] Gut. 2000 Jun;46(6):790-4 [10807889.001]
  • [Cites] Br J Surg. 1995 Nov;82(11):1540-3 [8535813.001]
  • [Cites] J Pathol. 1999 Mar;187(4):428-32 [10398102.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):564-7 [11870538.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Pathol Int. 1998 Aug;48(8):586-94 [9736405.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Br J Cancer. 1997;76(12):1604-9 [9413949.001]
  • [Cites] Cancer Res. 1987 Dec 15;47(24 Pt 1):6814-7 [3315192.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):450-4 [15816455.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):619-24 [11267970.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):407-17 [9121123.001]
  • [Cites] Eur J Surg Oncol. 1987 Dec;13(6):493-8 [3691822.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1620-7 [8608553.001]
  • [Cites] Gastroenterology. 1957 Jun;32(6):1095-103 [13438166.001]
  • [Cites] Int J Cancer. 2001 Nov 20;95(6):350-3 [11668515.001]
  • [Cites] J Pathol. 2001 Jul;194(3):334-40 [11439366.001]
  • [Cites] Pathol Int. 2001 Jun;51(6):445-51 [11422806.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):159-64 [9892201.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4595-7 [8062248.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):1-5 [10077143.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):316-21 [2547661.001]
  • [Cites] J Pathol. 2000 Jul;191(3):257-63 [10878546.001]
  • [Cites] Nat Med. 1996 Jun;2(6):630-1 [8640546.001]
  • (PMID = 17458592.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


60. Yu JW, Wu JG, Zheng LH, Zhang B, Ni XC, Li XQ, Jiang BJ: Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma. J Exp Clin Cancer Res; 2009;28:55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma.
  • BACKGROUND: To investigate influencing factors of the metastatic lymph nodes ratio (MLR) and whether it is related to survival in patients with gastric adenocarcinoma.
  • METHODS: We retrospectively evaluated the clinical features of 121 patients with gastric adenocarcinoma enrolled in our hospital between 2000 and 2007.
  • The MLR could also discriminate between subsets of patients with different 5-year survival periods within the same N stage (P < 0.05).
  • CONCLUSION: MLR is an independent prognostic factor in gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2008 Feb;31(1):79-83 [18376232.001]
  • [Cites] J Surg Res. 2008 Apr;145(2):238-43 [17603078.001]
  • [Cites] Br J Surg. 1997 Sep;84(9):1305-9 [9313721.001]
  • [Cites] World J Surg. 2002 Mar;26(3):323-9 [11865369.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):775-84 [12374661.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]
  • [Cites] J Surg Oncol. 1998 Sep;69(1):15-20 [9762886.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8239-48 [15548690.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 Apr 6;85(13):922-5 [16029534.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):534-40 [16705729.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):543-52 [17414602.001]
  • [Cites] Ann Surg Oncol. 2008 Mar;15(3):770-6 [18157577.001]
  • [Cites] Surg Oncol. 2008 Sep;17(3):203-10 [18539025.001]
  • (PMID = 19393100.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2689863
  •  go-up   go-down


61. Anderson C, Nijagal A, Kim J: Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther; 2006;10(6):345-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers for gastric adenocarcinoma: an update.
  • Gastric cancer is the second most common cancer worldwide.
  • Treatment of localized gastric cancer relies primarily on surgical intervention, although growing evidence suggests that the addition of chemoradiation may improve disease-free intervals and overall survival.
  • In this regard, the current high rates of recurrence and subsequent poor survival have prompted an ever-increasing use of multimodal strategies, even for early-stage disease.
  • [MeSH-major] Adenocarcinoma / therapy. Biomarkers, Tumor / analysis. Genetic Markers. Neoadjuvant Therapy / adverse effects. Pharmacogenetics / methods. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:71-81 [12775024.001]
  • [Cites] J Surg Oncol. 2006 Mar 1;93(3):241-52 [16482605.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):334-40 [16495697.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1883-91 [16622263.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1657-68 [10547537.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:55-69 [15591423.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2201-9 [10829039.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):206-15 [14710231.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Nov;21(6):673-8 [16220043.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):781-9 [15033468.001]
  • [Cites] J Am Soc Nephrol. 2003 Jan;14(1):1-10 [12506132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] Pharmacogenomics. 2004 Sep;5(6):627-41 [15335285.001]
  • [Cites] Acta Oncol. 2003;42(7):693-700 [14690154.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10(3):561-6 [12684624.001]
  • [Cites] World J Gastroenterol. 2004 Jan 15;10(2):172-6 [14716816.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):3249-52 [10652619.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):9-15 [14654896.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1976-83 [15928658.001]
  • [Cites] Tumori. 2005 Nov-Dec;91(6):513-21 [16457151.001]
  • [Cites] Cancer Sci. 2003 Apr;94(4):355-9 [12824904.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1469-74 [9626464.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):95-101 [10974411.001]
  • [Cites] Cell. 1993 Sep 24;74(6):957-67 [8402885.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3C):2149-53 [11501839.001]
  • [Cites] Cancer. 1990 Dec 1;66(11):2324-30 [1700927.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84 [14734480.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):484-9 [10507774.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12 ):714-9 [16303791.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Surg Today. 1998;28(6):595-8 [9681607.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Apr;4(4):350-66 [16569388.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Dec;129(12 ):727-34 [14557879.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1985;57:357-417 [3898742.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):170-8 [10450730.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1917-22 [9806649.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2288-93 [12805328.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Lett. 2002 Oct 28;184(2):197-206 [12127692.001]
  • [Cites] Suppl Tumori. 2003 Sep-Oct;2(5):S45-7 [12914390.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R207-14 [16244319.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6004-7 [14522928.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(2):256-63 [16356709.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):492-8 [16734727.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1394-400 [14508825.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2898-904 [12782596.001]
  • [Cites] Anticancer Drugs. 2004 Feb;15(2):85-106 [15075664.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3025-31 [15837757.001]
  • [Cites] J Cell Sci. 2003 Oct 15;116(Pt 20):4077-85 [12972501.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):21-7 [12004845.001]
  • [Cites] Int J Clin Oncol. 2005 Feb;10(1):5-13 [15729594.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4319-28 [15514373.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Jul;19(8 Suppl):1207-19 [1355336.001]
  • [Cites] Oncology. 2006;70(2):126-33 [16645325.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):228-40 [16344322.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):533-7 [16267625.001]
  • (PMID = 17154651.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 04ZR38536J / oxaliplatin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; U3P01618RT / Fluorouracil
  • [Number-of-references] 69
  •  go-up   go-down


62. Euanorasetr C, Lertsithichai P: Results of D2 gastrectomy for gastric adenocarcinoma: 10-year experience in Thai patients. J Med Assoc Thai; 2007 Feb;90(2):291-300
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of D2 gastrectomy for gastric adenocarcinoma: 10-year experience in Thai patients.
  • BACKGROUND: The therapeutic value of D2 gastrectomy in the curative treatment of gastric adenocarcinoma is controversial outside Japan.
  • MATERIAL AND METHOD: The authors retrospectively reviewed the medical records of 97 patients with gastric adenocarcinoma who underwent curative D2 gastrectomy between October 1995 and September 2005.
  • The 5-year disease-free survival rate for each TNM stage was 100% for stages IA and IB, 75% for stage II, 78% for stage IIIA, 28% for stage IIIB and 4% for stage IV.
  • CONCLUSION: The D2 gastrectomy can be performed with low morbidity and mortality, and may increase the cure rate and survival of Thai gastric adenocarcinoma patients, at least in experienced centers.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375634.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


63. Lau M, Le A, El-Serag HB: Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol; 2006 Nov;101(11):2485-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival.
  • BACKGROUND: Noncardia gastric adenocarcinoma is not frequently mentioned in the United States.
  • However, it is unclear if the previously reported decline in noncardia gastric adenocarcinoma has continued, and if detection and management has affected overall survival outside the setting of clinical trials.
  • METHODS: We used the Surveillance, Epidemiology, and End Results registry (SEER) to identify all cases of noncardia gastric adenocarcinoma diagnosed between 1973 and 2002.
  • RESULTS: Between 1973 and 2002, there were 24,103 cases of noncardia gastric adenocarcinoma.
  • However, the incidence of localized noncardia gastric adenocarcinoma (invasive neoplasm confined to the organ of origin) remained without change between 0.9 and 1.0 per 100,000 person-years, and increased with age, especially in the 85+ yr age group (a 47% increase between 1973 and 2002).
  • CONCLUSIONS: Despite the overall decline in noncardia gastric adenocarcinoma, the incidence of local stage disease has remained stable in most ages and even increased in old ages.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17029617.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, Tsujii S, Onishi S, Kobayashi M, Hanazaki K: Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg; 2008 Feb;206(2):306-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach?
  • BACKGROUND: Although the incidence of gastric cardia cancer is considerably less than more distal gastric cancer, the rate of occurrence is now increasing.
  • The objective of this study was to evaluate and compare the clinicopathologic findings of gastric cardia and more distal stomach adenocarcinoma.
  • STUDY DESIGN: Patients included in our study were those who underwent operations for gastric adenocarcinoma in our institute from 1981 to 2006, and who had undergone complete medical history, including history of daily alcohol consumption; smoking; body mass index; and pathologic examinations.
  • RESULTS: Among the 843 patients, 23 (2.8%) had gastric cardia cancer.
  • Although noncardia cancer was often detected at an early stage, gastric cardia cancer was most often diagnosed at an advanced stage.
  • CONCLUSIONS: Gastric cardia cancer occurs at a low incidence of only 2.8% of resected gastric cancers.
  • Unlike cases of gastric cardia cancer in Western populations, body mass index is not associated with occurrence of gastric cardia cancer in our study.
  • Because gastric cardia cancer appears more aggressive than noncardia gastric cancer, early diagnosis and intervention are important.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222384.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Richards DA, Boehm KA, Anthony SP: Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs; 2007 Jul;16(7):1059-68
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
  • Gastric cancer is a major worldwide problem and is a leading cause of death.
  • The incidence of distal gastric cancer is declining; however, there has been a rapid rise in the incidence of adenocarcinoma of the gastroesophageal junction, which is a more aggressive entity.
  • Despite these improvements, median survival remains at approximately 9 months in patients who are diagnosed at stage IV.
  • This review examines recent advances in the treatment of gastroesophageal junction adenocarcinoma and gastric cancer, newer agents and the potential agents that are in development, which can be logically applied to the treatment of this devastating disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594189.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 56
  •  go-up   go-down


66. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R: Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol; 2007 May;31(5):664-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.
  • Endocervical-type mucinous adenocarcinoma (ECA) of the uterine cervix is defined as a tumor composed of cells resembling those of the endocervical glands, but recent studies have demonstrated that a minority of ECAs displays a gastric immunophenotype.
  • The aim of this study was to assess the significance of the gastric phenotype.
  • Fifty-three cases of mucinous adenocarcinoma of the uterine cervix (37 FIGO stage IB, 4 stage IIA, and 12 stage IIB) were reviewed and reevaluated using a newly established morphologic criteria for distinguishing gastric type adenocarcinoma, which was defined as a tumor showing clear and/or pale eosinophilic and voluminous cytoplasm, with distinct cell borders.
  • The results were correlated with gastric immunophenotype, determined by HIK1083 and MUC6 immunostaining, and patient outcome.
  • Following the current World Health Organization scheme (2003), 47 tumors (89%) were classified as ECA, 1 (2%) as intestinal type, 1 (2%) as mixed endocervical and intestinal type, and 4 (8%) as minimal deviation adenocarcinoma.
  • Twelve of 47 (26%) ECAs and all 4 minimal deviation adenocarcinomas, reclassified as gastric type using the novel criteria, were frequently positive for HIK1083 with a rate of 75% (12/16), whereas only 11% (4/37) of nongastric tumors were positive.
  • There was no significant difference in MUC6 reactivity between gastric and nongastric type tumors (31%, 5/16 vs. 16%, 6/37; P=0.4).
  • Patients with gastric-type adenocarcinomas had a significantly decreased 5-year disease-specific survival rate (30 vs. 77%; P<0.0001), and the gastric type morphology was related to a significant risk for disease recurrence compared with the nongastric type (P=0.001; HR, 4.5; 95% confidence interval, 1.42-14.2).
  • Mucinous adenocarcinoma of the uterine cervix with gastric immunophenotype can be a distinct morphologic variant showing an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastric Mucosa / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers, Tumor / metabolism. Disease-Free Survival. Female. Gastric Mucins / immunology. Gastric Mucins / metabolism. Humans. Immunophenotyping. Japan / epidemiology. Middle Aged. Neoplasm Staging. Retrospective Studies. Staining and Labeling. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460448.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Gastric Mucins
  •  go-up   go-down


67. Kuruba R, Jawad M, Karl RC, Murr MM: Technique of resection of esophageal adenocarcinoma after Roux-en-Y gastric bypass and literature review of esophagogastric tumors after bariatric procedures. Surg Obes Relat Dis; 2009 Sep-Oct;5(5):576-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technique of resection of esophageal adenocarcinoma after Roux-en-Y gastric bypass and literature review of esophagogastric tumors after bariatric procedures.
  • However, experience with tumors arising in the esophagus or stomach after gastric bypass is lacking.
  • We report our technique for curative resection of esophageal adenocarcinoma in a patient who had undergone previous gastric bypass and review the reported data on esophagogastric tumors after bariatric surgery.
  • METHODS: We have described the operative details of esophagectomy after gastric bypass and reviewed the published data regarding type of bariatric surgery, gender predilection, presentation, symptom duration, cancer stage, and prognosis of patients with esophagogastric tumors occurring after bariatric surgery.
  • This operative technique pays particular attention to the altered anatomy, dissection of the gastric pouch, and preservation of the blood supply to the excluded stomach.
  • This technique can also be applied to manage tumors arising in the gastric pouch after previous gastric bypass.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Obesity, Morbid / surgery
  • [MeSH-minor] Gastric Bypass. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640802.001).
  • [ISSN] 1878-7533
  • [Journal-full-title] Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • [ISO-abbreviation] Surg Obes Relat Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


68. Jeon J, Luebeck EG, Moolgavkar SH: Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control; 2006 Sep;17(7):971-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States).
  • A number of hypotheses have been advanced to explain the rapid increase of the incidence of esophageal adenocarcinoma in the US.
  • To address this problem, we have developed multi-stage carcinogenesis models that describe the age-specific incidence of adenocarcinoma of the esophagus and of the gastric cardia with separate adjustments for temporal trends.
  • We fit these models separately to the incidence of adenocarcinoma of the esophagus and of the gastric cardia reported in the Surveillance Epidemiology and End Results (SEER) registry over the period 1973-2000.
  • We conclude that the incidence of both cancers is consistent with a sequence that posits a tissue conversion step in the target organ followed by a multi-stage process with three rate-limiting events, the first two leading to an initiated cell that can expand clonally into a premalignant lesion, and the third converting an initiated cell into a malignant cell.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841264.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA047658; United States / NCI NIH HHS / CA / R01 CA119224-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


69. Kostić Z, Cuk V, Ignjatović M, Usaj-Knezević S: [Early complications following radical surgical treatment of patients with gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Mar;63(3):249-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early complications following radical surgical treatment of patients with gastric adenocarcinoma].
  • BACKGROUND/AIM: Surgical treatment of patients with gastric adenocarcinoma means the total excision of a tumor and the pathways of its spreading with the risk of operational complications as low as possible.
  • The aim of this study was to evaluate the type and frequency of early postoperative complications and mortality after a radical surgical treatment of patients with gastric adenocarcinoma.
  • Three of four deaths occured in patients older than 70 years, with the stage III and IV of the disease, and in all of them total gastrectomy with splenectomy was performed.
  • CONCLUSION: Radical surgical treatment of patients with gastric adenocarcinoma might be done with an acceptable morbidity and mortality if it is performed by the surgeons with the experience in D2 lymphadenectomy technique.
  • [MeSH-major] Adenocarcinoma / surgery. Postoperative Complications. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16605190.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


70. Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY: Prognosis of pN3 stage gastric cancer. Cancer Res Treat; 2009 Jun;41(2):73-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of pN3 stage gastric cancer.
  • PURPOSE: The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features.
  • MATERIALS AND METHODS: Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer.
  • We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis.
  • RESULTS: Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3.
  • Among these 260 patients, 78 patients were classified as the pN3/M1 stage.
  • The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients.
  • CONCLUSION: The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group.
  • An advanced T stage was a predictor for a poor prognosis for the pN3 patients.
  • Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):118-22 [17262741.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2535-42 [17549571.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):187-92 [17611776.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):1959-67 [18369676.001]
  • [Cites] J Gastrointest Surg. 2008 Aug;12(8):1364-9 [18516653.001]
  • [Cites] Arch Surg. 2009 Jan;144(1):38-45; discussion 45 [19153323.001]
  • [Cites] J Surg Oncol. 2009 May 1;99(6):324-8 [19204941.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Aug;71(2):127-64 [19230702.001]
  • [Cites] World J Surg. 1999 May;23(5):492-7; discussion 497-8 [10085399.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):64-71 [11139315.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):215-21 [11314937.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] Am J Surg. 2004 Apr;187(4):543-6 [15041508.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • (PMID = 19707504.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2731212
  • [Keywords] NOTNLM ; Advanced gastric cancer / Prognosis / Prognostic factor / Survival / pN3
  •  go-up   go-down


71. Sugiura T, Miyamoto K: Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC protein. J Cell Biochem; 2008 Nov 1;105(4):1081-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC protein.
  • To explore the molecules associated with gastric adenocarcinoma, we used the gene expression profile database of various human tissues and identified TRIM31 upregulated in both patients with chronic gastritis and stomach cancer.
  • Thus, TRIM31 is a characteristic RBCC protein with the ability to regulate cell proliferation negatively and may be a potential biomarker of gastric cancer as it is overexpressed from the early stage of gastric carcinogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773414.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; EC 6.3.2.- / TRIM31 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


72. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol; 2005 Jun 1;90(3):139-46; discussion 146
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.
  • A topographic-anatomic subclassification of adenocarcinomas of the esophago-gastric junction (AEG) in distal esophageal adenocarcinoma (AEG Type I), true carcinoma of the cardia (AEG Type II), and subcardial gastric cancer (AEG Type III) was introduced in 1987 and is now increasingly accepted and used worldwide.
  • Stage distribution and overall long-term survival after surgical resection also shows marked differences between the AEG subtypes.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms / classification. Esophagogastric Junction. Stomach Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15895452.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


73. Nagahori Y, Nagahori K, Hamaguchi Y, Fukushima T, Masui H, Mogaki M, Abe T: [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1555-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
  • Several chemotherapy regimens combining CPT-11 and CDDP for advanced gastric cancer have been reported to demonstrate high response rates and high incidence of severe toxicity.
  • PATIENTS AND METHODS: Seven patients with histologically-confirmed intestinal type of gastric adenocarcinoma were enrolled in this study.
  • Six patients received combination chemotherapy with CPT-11 and CDDP after the gastrectomy (stage I b: 1, II : 3, III b: 1, IV: 1).
  • CONCLUSION: The combination of low-dose CDDP and CPT-11 has mild therapeutic toxicities and may achieve a prolonged median survival time in patients with intestinal- type gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799911.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


74. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ: The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol; 2008 Jul;15(7):1968-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma.
  • In this study, we used immunohistochemistry to evaluate the patterns of histone H3 and H4 acetylation and trimethylation in gastric adenocarcinomas.
  • METHODS: Double 2-mm core tissue microarrays were made from 261 paraffin-embedded gastric adenocarcinoma samples and examined by immunohistochemistry for histone H3 lysine 9 (H3K9) acetylation and trimethylation, histone H4 lysine 16 acetylation, and histone H4 lysine 20 trimethylation.
  • RESULTS: Trimethylation of H3K9 positively correlated with tumor stage (P = 0.043); lymphovascular invasion (P = 0.029), cancer recurrence (P = 0.043), and higher level of H3K9 trimethylation correlated with a poor survival rate (P = 0.008).
  • CONCLUSION: The pattern of histone modification as detected by immunohistochemistry may be useful as a predictor for the recurrence of cancer and may be an independent prognostic factor in gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. DNA Methylation. Histones / metabolism. Neoplasm Recurrence, Local / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Jul;16(7):2077-8 [19408053.001]
  • (PMID = 18470569.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones
  •  go-up   go-down


75. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, Matsuzaki T, Noda S, Kubo N, Tanaka H, Doi Y, Ohira M, Muguruma K, Sawada T, Hirakawa K: Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer; 2010;10:652
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated smad2 in advanced stage gastric carcinoma.
  • BACKGROUND: Transforming growth factor β (TGFβ) receptor signaling is closely associated with the invasion ability of gastric cancer cells.
  • Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma.
  • The aim of the current study is to clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages.
  • METHODS: Immunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens from 135 patients with advanced gastric adenocarcinomas.
  • We also evaluated the relationship between the expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas.
  • RESULTS: The p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas.
  • CONCLUSION: The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Peritoneal Neoplasms / chemistry. Smad2 Protein / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2010 Mar 2;102(5):844-51 [20145621.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9107-11 [19010878.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):497-505 [11809701.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):230-4 [12824914.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):302-12 [12967141.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8848-52 [14695201.001]
  • [Cites] Int J Cancer. 1989 Sep 15;44(3):394-8 [2777404.001]
  • [Cites] Br J Cancer. 1994 Apr;69(4):777-83 [8142266.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1096-103 [8855981.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):582-7 [9778627.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):893-900 [15546507.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):451-5 [16053517.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84 [16105881.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Feb;21(2):432-7 [16509870.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):51-6 [16788944.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):147-60 [17292826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3460-5 [17307870.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2850-60 [18451253.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4489-93 [11205293.001]
  • (PMID = 21110833.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / Smad2 Protein
  • [Other-IDs] NLM/ PMC3001722
  •  go-up   go-down


76. Kostić Z, Cuk V, Bokun R, Ignjatović D, Usaj-Knezević S, Ignjatović M: [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Apr;63(4):349-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma].
  • BACKGROUND/AIM: Peritoneal metastasis is a leading cause of therapeutic failure after an operative treatment of patients with gastric adenocarcinoma.
  • The aim of this study was to determine the frequency of the presence of free cancer cells in the peritoneal cavity in the patients surgically treated for gastric adenocarcinoma, and its relation to certain clinical, operative and pathohistological paramethers.
  • Immediately after the laparotomy, 200 ml physiologic saline, heated to 37 degrees C, was introduced into the abdominal cavity, mannualy dispersed and collected from the region around the gastric tumor and the pouch of Douglas.
  • The frequency of positive cytological findings was compared to the location and the diameter of the cancer, pathohistological type of carcinoma, pathohistological stage of the disease, lymph node and the liver and/or peritoneal metastases and the type of surgical procedure.
  • A statistically highly significant difference (p < or = 0.001) in the frequency of positive cytological finding was found between the groups of patients with and without cancer invasion of serosa, with cancer diameters > 5 cm and < or = 5 cm, in the stage of disease I, II and III, IV, with macroscopically present and without metastases, with re section and D2 lymphadenectomy and palliative procedure.
  • The results of the univariate analysis showed that the cancer diameter > 5 cm, tumor invasion of serosa, pathohistological stage of the disease III and IV and macroscopically visible metastases were the most important risk factors for the free cancer cells detection.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Neoplastic Cells, Circulating. Peritoneal Cavity / cytology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Apr;63(4):347-8 [16683400.001]
  • (PMID = 16683401.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


77. Senapati S, Chaturvedi P, Sharma P, Venkatraman G, Meza JL, El-Rifai W, Roy HK, Batra SK: Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. Br J Cancer; 2008 Sep 16;99(6):949-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer.
  • To date, no extensive study has been done to check the expression and functional significance of MUC4 in different types of gastric adenocarcinomas.
  • Here, we report the expression profile of MUC4 in gastric adenocarcinomas and its function in poorly differentiated gastric non-signet ring cell carcinoma (non-SRCC) type cells.
  • Immunohistochemical analysis using tissue microarray (TMA) showed a significant difference in MUC4 expression between normal adjacent (n = 45) and gastric adenocarcinoma (n = 83; P < 0.001).
  • MUC4 expression was not associated with tumour type, stage or with the degree of differentiation.
  • To gain further insight into the significance of MUC4 expression in gastric non-SRCC cells, MUC4 was ectopically expressed in AGS, a poorly differentiated gastric non-signet ring cell line.
  • In conclusion, our results showed that MUC4 is overexpressed in gastric adenocarcinoma tissues, and that it has a role in promoting aggressive properties in poorly differentiated gastric non-SRCC cells through the activation of the ErbB2 oncoprotein.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 30;355(1):200-3 [17292332.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):622-30 [14744777.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):345-57 [17595659.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]
  • [Cites] Gastric Cancer. 2004;7(1):9-16 [15052434.001]
  • [Cites] Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32 [15284539.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1703-9 [6831414.001]
  • [Cites] Med J Aust. 1985 Feb 4;142(3):S5-6 [3969029.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):1072-6 [2471698.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):6966-71 [2582438.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1941s-1943s [8137316.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):160-72 [8020658.001]
  • [Cites] Cancer Detect Prev. 1995;19(2):173-82 [7750105.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):455-64 [9247464.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1056-65 [9308730.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33245-54 [9407114.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):133-8 [9583726.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):402-10 [9699534.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2605-14 [9829723.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):214-9 [10440758.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):559-64 [16098726.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):1048-56 [18397823.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Apr;1(2):219-29 [10887495.001]
  • [Cites] Gut. 2000 Sep;47(3):349-56 [10940270.001]
  • [Cites] J Histochem Cytochem. 2000 Dec;48(12):1657-66 [11101634.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5680-9 [11114748.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Br J Surg. 2003 Jan;90(1):95-101 [12520583.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):683-94 [12640674.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6107-10 [12955090.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35458-64 [12826677.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • (PMID = 18781152.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA093999; United States / NCI NIH HHS / CA / CA78590; United States / NCI NIH HHS / CA / CA111294
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-4; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS106794; NLM/ PMC2538752
  •  go-up   go-down


78. Patriti A, Ceccarelli G, Bellochi R, Bartoli A, Spaziani A, Di Zitti L, Casciola L: Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma. Surg Endosc; 2008 Dec;22(12):2753-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma.
  • BACKGROUND: Lymph node dissection and esophageal anastomosis, considered the more demanding steps of laparoscopic gastrectomy for gastric adenocarcinoma, can be performed with the use of a remote-controlled robot.
  • METHODS: Thirteen patients with a histologically proved gastric cancer (six stage I, six stage II, and one stage III) were enrolled in a prospective study to assess feasibility and safety of the Da Vinci surgical system in total and partial gastrectomy with extended lymph node dissection.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Laparoscopy / methods. Lymph Node Excision / methods. Robotics / methods. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2009 Aug;23(8):1919-21; author reply 1922-3 [19444513.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):348-54 [17091331.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):169-72 [18095269.001]
  • [Cites] Am J Surg. 2007 Dec;194(6):839-44; discussion 844 [18005781.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1390-7 [15386325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):645-50 [11395231.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):139-46; discussion 146 [15895452.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):777-84 [12860761.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Int J Clin Pract. 2007 Feb;61(2):309-14 [17263718.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):436-42 [17593437.001]
  • [Cites] Surg Oncol. 1993;2 Suppl 1:13-8 [8252217.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1662-6 [17345142.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22 [11981334.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jun;127(6):1847-9 [15173760.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] Surg Endosc. 2007 Jul;21(7):1054-62 [17287918.001]
  • [Cites] Ann Surg Oncol. 2000 Apr;7(3):210-7 [10791852.001]
  • [Cites] Gastric Cancer. 2006;9(3):167-76 [16952034.001]
  • [Cites] Acta Biomed. 2004 Dec;75(3):188-91 [15796094.001]
  • [Cites] Surg Oncol. 2007 Aug;16(2):85-98 [17560103.001]
  • [Cites] Gastric Cancer. 2004;7(4):240-5 [15616772.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Surg Endosc. 2008 Mar;22(3):784-6 [17943373.001]
  • (PMID = 18813994.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, Kim S, Lim DH, Kim KM, Kang WK: Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res; 2008 Jan 1;14(1):82-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
  • PURPOSE: There are no reliable prognostic markers that identify gastric cancer patients who may benefit from adjuvant chemoradiation therapy.
  • Therefore, we analyzed expression and prognostic significance of E2F-1 along with thymidylate synthase (TS) in R(0)-resected gastric adenocarcinoma patients, who underwent adjuvant chemoradiation therapy with 5-fluorouracil (5-FU) and leucovorin.
  • EXPERIMENTAL DESIGN: The chemosensitivity to 5-FU and radiosensitivity were tested in three E2F-1-overexpressed gastric cancer cell lines in vitro.
  • The expressions of TS and E2F-1 were analyzed in 467 R(0)-resected primary gastric cancer patients, who received adjuvant chemoradiation therapy with 5-FU and leucovorin using tissue microarray.
  • However, the E2F-1 immunopositivity did not retain its statistical significance at multivariate analysis for predicting disease-free survival (data not shown, P = 0.270), but stage was the only influential factor for disease-free survival in stages IB to IV (M(0)) patients (P < 0.001).
  • CONCLUSION: E2F-1 is a potentially novel independent prognostic factor that may identify gastric cancer patients who will likely benefit from adjuvant chemoradiation therapy following curative resection.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. E2F1 Transcription Factor / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172256.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E2F1 Transcription Factor; EC 2.1.1.45 / Thymidylate Synthase; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


80. Ke B, Liang H, Zhang RP, Wang XJ, Wang G, Zhao JZ: [Prognostic analysis on primary duodenal adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May;13(5):357-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis on primary duodenal adenocarcinoma].
  • OBJECTIVE: To investigate the prognostic factors of primary duodenal adenocarcinoma.
  • METHODS: The medical records of 67 patients with primary duodenal adenocarcinoma treated in our hospital from January 1990 to December 2005 were retrospectively analyzed.
  • Univariable analysis showed that T-stage, nodal metastasis and tumor stage had significant negative effects on the survival of patients who underwent curative resection.
  • However, multivariable analysis revealed that T-stage and nodal metastasis were significantly associated with survival.
  • T-stage and lymph nodes metastasis are associated with decreased survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Duodenal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499305.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


81. Wang Q, Gong L, Dong R, Qiao Q, He XL, Chu YK, Du XL, Yang Y, Zang L, Nan J, Lin C, Lu JG: Tissue microarray assessment of selenoprotein P expression in gastric adenocarcinoma. J Int Med Res; 2009 Jan-Feb;37(1):169-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray assessment of selenoprotein P expression in gastric adenocarcinoma.
  • This study investigated selenoprotein P expression, using immunohistochemistry, in gastric adenocarcinoma tissue microarrays constructed from 30 gastric adenocarcinoma specimens and 30 normal gastric tissues (controls).
  • Selenoprotein P expression scores were significantly lower in gastric adenocarcinoma (17/30, 56.7%) than in control tissues (25/30, 83.3%).
  • Selenoprotein P was significantly more likely to be expressed in well-to-moderately differentiated cases (13/17, 76.5%) than in cases with low differentiation (4/13, 30.8%) and there was no significant difference in selenoprotein P expression between tumour node metastasis (TNM) stage I - II (11/19, 57.9%) and TNM stage III (6/11, 54.5%).
  • In conclusion, selenoprotein P expression was low in gastric adenocarcinoma tissues compared with control tissues and was related to the degree of gastric adenocarcinoma differentiation but not to TNM stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215687.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Selenoprotein P
  •  go-up   go-down


82. Iatsenko LD: [The survival indices of patients with stage IV gastric cancer treated by polyplatilen]. Klin Khir; 2007 Aug;(8):50-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The survival indices of patients with stage IV gastric cancer treated by polyplatilen].
  • The survival indices of patients suffering gastric cancer stage IV in application of cytostatic preparation polyplatilen were studied up.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318072.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / cisplatin-DNA adduct; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Li M, Gu Y, Zhang Z, Zhang S, Zhang D, Saleem AF, Zhao X, Sun B: Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res; 2010 Jun;16(2):259-66
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma.
  • Till now, there is no report about VM in gastric adenocarcinoma (GAC).
  • Cox proportional hazards model indicated that the presence of VM and TNM stage were independent predictors of poor prognosis (P = 0.039 and 0.004) for GAC.
  • [MeSH-major] Adenocarcinoma / pathology. Neovascularization, Pathologic / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 2002;19(3):233-46 [12067204.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):444-51 [18261629.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:151-61 [12814947.001]
  • [Cites] Front Biosci. 2006 May 01;11:1696-701 [16368548.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11520-8 [16357161.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):149-54 [16847924.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6322-7 [11522618.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5470-5 [12359755.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1609-14 [15547697.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4757-62 [12941789.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2533-9 [12147581.001]
  • [Cites] Gastrointest Cancer Res. 2008 May;2(3):113-25 [19259290.001]
  • [Cites] Am J Obstet Gynecol. 2004 Apr;190(4):899-909 [15118611.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):508-25 [15563313.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):188-97 [16997457.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1279-88 [11290546.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1566-77 [12085206.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 [11181773.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):325-35 [15935515.001]
  • [Cites] Eye (Lond). 1997;11 ( Pt 2):227-38 [9349418.001]
  • [Cites] Oncology. 2007;72(1-2):111-7 [18025805.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):821-8 [12115483.001]
  • [Cites] Presse Med. 2007 Dec;36(12 Pt 2):1782-6 [17587539.001]
  • [Cites] Radiographics. 1999 Nov-Dec;19(6):1435-46 [10555667.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):693-8 [16969481.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):281-90 [17603752.001]
  • [Cites] J Soc Gynecol Investig. 2002 Jan-Feb;9(1):2-9 [11839501.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2792-805 [16290133.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):445-51 [11212228.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13 [11121063.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):639-46 [16739333.001]
  • [Cites] World J Gastroenterol. 2006 Dec 21;12(47):7598-603 [17171787.001]
  • (PMID = 20016961.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Keratin-18; 0 / Keratin-8; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


84. Choi MG, Sung CO, Noh JH, Kim KM, Sohn TS, Kim S, Bae JM: Mucinous gastric cancer presents with more advanced tumor stage and weaker β-catenin expression than nonmucinous cancer. Ann Surg Oncol; 2010 Nov;17(11):3053-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous gastric cancer presents with more advanced tumor stage and weaker β-catenin expression than nonmucinous cancer.
  • BACKGROUND: Mucinous gastric carcinoma (MGC) is a rare type of gastric cancer; its biological behavior is controversial.
  • We also compared the expression patterns of CDX-2 and β-catenin between MGC and nonmucinous gastric carcinoma (NMGC).
  • METHODS: We reviewed the records of 9218 patients with gastric cancer who underwent gastric cancer surgery between January 1997 and December 2006.
  • In addition, MGC had deeper invasion, more lymph node and lymphatic involvement, a more advanced tumor stage, and lower 5-year survival rates than NMGC.
  • CONCLUSIONS: MGC presents at a more advanced stage and was larger than NMGC.
  • The poor prognosis of MGC was related to the more advanced tumor stage at diagnosis; the histological type was not an independent prognostic factor.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. beta Catenin / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645013.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin
  •  go-up   go-down


85. Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol; 2007 Oct;14(10):2748-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
  • However, the role of CD24 in gastric adenocarcinoma remains largely unknown.
  • METHODS: The expression pattern of CD24 in 103 gastric adenocarcinomas (31 diffuse type, 60 intestinal type, and 12 mixed type) was analyzed by immunohistochemistry.
  • RESULTS: Cytoplasmic CD24 expression occurred in 50% of the gastric adenocarcinoma patients and was associated with high-stage tumor (Stage III-IV, P = .023), serosal invasion (SI, P = .010), lymphovascular invasion (LVI, P = .039), and lower 10-year survival (P = .0238).
  • The CD24 staining pattern was different in intestinal and diffuse-type gastric adenocarcinomas.
  • Further analysis showed that cytoplasmic CD24 expression was, in fact, correlated with high-stage tumor, SI, LVI, and lower 10-year survival significantly (P = .020, P = .007, P = .018, P = .0285, respectively) in diffuse-type gastric adenocarcinoma.
  • Moreover, multivariate analysis showed that cytoplasmic CD24 expression was an independent risk factor of SI and LVI respectively (P = .0083 and P = .0019), and thus it contributed to high-stage tumor and poor patient survival in diffuse- or mixed-type gastric adenocarcinoma.
  • CONCLUSIONS: Cytoplasmic expression of CD24 was associated with invasiveness and poorer prognosis and can serve as a novel target for prognostic prediction and adjuvant treatment of patients with diffuse-type gastric adenocarcinoma after tumor resection.
  • [MeSH-major] Adenocarcinoma / pathology. Antigens, CD24 / analysis. Biomarkers, Tumor / analysis. Cytoplasm / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680316.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


86. Dickey A, Hrom J: A rare case of signet ring cell gastric adenocarcinoma. J Miss State Med Assoc; 2007 Sep;48(9):271-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of signet ring cell gastric adenocarcinoma.
  • Although the incidence and mortality rates continue to decline in the United States, gastric cancer remains one of the leading causes of cancer mortality worldwide.
  • Signet Ring Cell gastric cancer is a rare and distinct histological subtype.
  • The patient was found to have a large, obstructing antral mass that was biopsied by esophagogastroduodenoscopy (EGD) and revealed Signet Ring Cell gastric adenocarcinoma.
  • Gastric carcinoma frequently requires a multi-disciplinary approach to properly diagnose, stage, and treat.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Gastric Bypass. Stomach Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292116.001).
  • [ISSN] 0026-6396
  • [Journal-full-title] Journal of the Mississippi State Medical Association
  • [ISO-abbreviation] J Miss State Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10.
  • Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases.
  • The incidence of undifferentiated-type tumours was significantly higher in cases with advanced-stage C-Ca than in those with early-stage C-Ca (5 vs 36.5%, P=0.0076).
  • A significantly greater frequency of HGM expression in early-stage C-Ca and significantly lower frequency of MUC2 expression in advanced-stage C-Ca was observed as compared with the corresponding values in cases of D-Ca (78.9 vs 52.2%, P=0.0402 and 51.5 vs 84.6%, P=0.0247, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


88. Budisin NI, Majdevac IZ, Budisin ES, Manic D, Patrnogic A, Radovanovic Z: Surgery for patients with gastric cancer in the terminal stage of the illness - TNM stage IV. J BUON; 2009 Oct-Dec;14(4):593-603
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for patients with gastric cancer in the terminal stage of the illness - TNM stage IV.
  • PURPOSE: To assess any survival advantage in patients with incurable gastric cancer who had undergone resection, bypass or exploratory surgery.
  • Incurable gastric cancer was defined as TNM stage IV disease: locally advanced (LA), with solitary distant metastasis (SM) or with multiple metastases and/or peritoneal carcinomatosis (MMC).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148448.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


89. Alexander JS, Mathis JM, Pruitt K: Interaction of microsatellite instability and loss of heterozygosity in adenocarcinoma: multiple markers in adenocarcinoma: an introduction to 'Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA'. Eur J Gastroenterol Hepatol; 2007 Dec;19(12):1038-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interaction of microsatellite instability and loss of heterozygosity in adenocarcinoma: multiple markers in adenocarcinoma: an introduction to 'Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA'.
  • Gastric cancer is the second most frequent cause of cancer death worldwide, yet the precise mechanisms underlying the different subtypes of gastric carcinogenesis are poorly understood.
  • Improvements in the diagnosis and prognosis of gastric cancer over classical clinicopathologic findings such as TNM stage, age or macroscopic tumor type, now include novel techniques for superficial endoscopic examination, and new strategies for genetically analyzing biopsied specimens.
  • The development of gastric adenocarcinomas, such as that of many tumor classes, represents the cumulative effects of several different types of mutations, and it is now recognized that both the loss of normal DNA repair, as well as the mutation, loss or inhibition of tumor suppressor genes contribute to the genetic instability leading to cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Loss of Heterozygosity. Microsatellite Instability. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1082-9 [17998833.001]
  • (PMID = 17998824.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  • [Number-of-references] 14
  •  go-up   go-down


90. Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z, Kuang G: Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol; 2010;2010:721485
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma.
  • AIM: Investigate the promoter methylation of the Thrombospondin-1 (TSP1) gene in gastric cardia adenocarcinoma (GCA).
  • The protein expression of TGF-beta1 was significantly higher in tumor tissues (P < .001) and was associated with TNM stage and histological differentiation.
  • [MeSH-major] Adenocarcinoma / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics. Thrombospondin 1 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2003 Jan 15;116(Pt 2):217-24 [12482908.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):509-19 [11980922.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6299-310 [14559817.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):245-58 [15036264.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):961-8 [15094109.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Jan;68(1):240-3 [5276296.001]
  • [Cites] Blood. 1985 Jan;65(1):79-84 [3965054.001]
  • [Cites] J Cell Biol. 1985 Sep;101(3):1059-70 [4030891.001]
  • [Cites] J Cell Biol. 1989 Feb;108(2):719-27 [2493001.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):755-61 [2714880.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2899-903 [8428963.001]
  • [Cites] J Cell Biol. 1993 Aug;122(4):923-32 [8349738.001]
  • [Cites] Int J Cancer. 1994 Oct 15;59(2):191-5 [7927918.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] J Cell Sci. 1995 Feb;108 ( Pt 2):797-809 [7539439.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1183-91 [8751720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1793-801 [9528751.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):733-40 [16075282.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):3534-41 [16951312.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3112-20 [16835379.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5930-9 [17442977.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):14-21 [18425817.001]
  • [Cites] Cell. 2008 Aug 8;134(3):392-404 [18692464.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7090-9 [18757424.001]
  • [Cites] Curr Drug Targets. 2008 Oct;9(10):842-50 [18855618.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):2947-54 [10706681.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):597-614 [11102749.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2427-36 [11160302.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Oncology. 2003;64(4):423-9 [12759541.001]
  • (PMID = 20300551.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thrombospondin 1
  • [Other-IDs] NLM/ PMC2838370
  •  go-up   go-down


91. Lin SZ, Tong HF, You T, Yu YJ, Wu WJ, Chen C, Zhang W, Ye B, Li CM, Zhen ZQ, Xu JR, Zhou JL: Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol; 2008 Feb;134(2):187-92
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative gastrectomy and chemotherapy for stage IV gastric cancer.
  • PURPOSE: To investigate the value of palliative gastrectomy and chemotherapy in a large series of patients with stage IV gastric cancer.
  • PG combined with adjuvant chemotherapy may improve survival in patients with stage IV gastric cancer, even with liver metastasis, peritoneal dissemination, and lymph node metastasis.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1998 Sep;69(1):41-4 [9762890.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1585-95 [15520058.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2307-11 [9635521.001]
  • [Cites] Semin Surg Oncol. 1994 Mar-Apr;10(2):117-20 [8052780.001]
  • [Cites] Cancer. 1958 Jan-Feb;11(1):28-32 [13500292.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1863-8 [1717128.001]
  • [Cites] Am J Surg. 2004 Apr;187(4):543-6 [15041508.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):65-9 [9208963.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Surg Today. 1995;25(11):959-61 [8640021.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jul;13(3):455-66, viii [15236728.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):490-3 [9068476.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):204-13 [16482619.001]
  • [Cites] Surgery. 1991 Nov;110(5):820-3 [1948650.001]
  • [Cites] Am Surg. 1999 Apr;65(4):352-5 [10190362.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):36-40 [8841464.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):215-21 [11314937.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):372-9 [16489635.001]
  • (PMID = 17611776.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Yoon CS, Hyung WJ, Lee JH, Chae YS, Won NH, Yeom BW, Choi JS: Expression of S100A4, E-cadherin, alpha- and beta-catenin in gastric adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1916-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of S100A4, E-cadherin, alpha- and beta-catenin in gastric adenocarcinoma.
  • BACKGROUND/AIMS: This investigation aimed to elucidate the expression patterns of S100A4 and adhesion molecules in gastric carcinoma and to estimate their correlation with clinicopathologic parameters.
  • METHODOLOGY: The expression of S100A4, E-cadherin, alpha- and beta-catenin was studied in 251 gastric carcinoma specimens through immunohistochemical staining.
  • RESULTS: The positive expression of S100A4 was significantly associated with advanced gastric cancer, higher pTNM stage, and poorer survival rates, especially when present in nuclear staining.
  • The reduced expression of adhesion molecules was significantly associated with diffuse type of gastric cancer.
  • The reduced expression of beta-catenin was significantly associated with lymph node metastasis, especially in early gastric cancer.
  • The coexpression status of S100A4-positive and reduced beta-catenin was significantly associated with larger tumor size, advanced tumor depth, and higher pTNM stage.
  • CONCLUSIONS: S100A4 and adhesion molecule expression may be a useful prognostic marker for individual gastric cancer patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Cadherins / analysis. S100 Proteins / analysis. Stomach Neoplasms / chemistry. alpha Catenin / analysis. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102422.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / S100 Proteins; 0 / alpha Catenin; 0 / beta Catenin; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


93. Wu Y, Guo E, Yu J, Xie Q, Chen J: High DcR3 expression predicts stage pN2 in gastric cancer. Hepatogastroenterology; 2007 Oct-Nov;54(79):2172-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High DcR3 expression predicts stage pN2 in gastric cancer.
  • METHODOLOGY: This prospective study evaluated the DcR3 tissue status by RT-PCR and its correlation with the lymph node (N) stages in 62 primary gastric cancers.
  • Using ROC analysis, a cut-off level of DcR3 expression at 1.20 was found to be associated with optimal sensitivity and specificity of 62.5% (15/24) and 92.1% (35/38) respectively, in the prediction of stage pN2.
  • Logistic regression analysis for stage pN2 revealed that high DcR3 expression was an independent risk factor.
  • CONCLUSIONS: Gastric cancer patients with high DcR3 expression presented more advanced pN2 disease than those with low DcR3 expression.
  • Preoperative checking DcR3 expression might be an additional approach to imaging modalities for evaluating N stages in gastric cancer to guide the operative procedures.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Receptors, Tumor Necrosis Factor, Member 6b / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Oncol. 2008 Jun;31(3):310 [18546592.001]
  • (PMID = 18251184.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Duplicate Publication; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


94. Huang CC, Lien HH, Wang PC, Yang JC, Cheng CY, Huang CS: Quality of life in disease-free gastric adenocarcinoma survivors: impacts of clinical stages and reconstructive surgical procedures. Dig Surg; 2007;24(1):59-65
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in disease-free gastric adenocarcinoma survivors: impacts of clinical stages and reconstructive surgical procedures.
  • AIM: To investigate health-related quality of life data of disease-free gastric adenocarcinoma survivors, with special emphasis on the roles of clinical stages and reconstructive surgical procedures.
  • METHODS: We performed a cross-sectional study in 51 disease-free gastric adenocarcinoma patients.
  • The Taiwan Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer 30 (EORTC QLQ-C30) and the supplementary gastric cancer module QLQ-STO22 were used as outcome measures.
  • RESULTS: Patients with earlier-/advanced-stage diseases (American Joint Committee on Cancer stages I and II vs. III and IV) had a similar quality of life in terms of global health status and functional and symptomatic well-being.
  • Multivariate regression analyses also proved that proximal gastric preservation was predictive of better role function, less nausea/vomiting, and less appetite loss.
  • CONCLUSIONS: Gastric adenocarcinoma survivors may enjoy a similar life quality, regardless of their original disease stages.
  • [MeSH-major] Adenocarcinoma / surgery. Quality of Life. Reconstructive Surgical Procedures. Stomach Neoplasms / surgery. Survivors

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17369683.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


95. Ozdemir NY, Abali H, Oksüzoğlu B, Budakoglu B, Uncu D, Güler T, Odabaşi H, Zengin N: The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol; 2010 Sep;27(3):680-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
  • Patients with advanced gastric carcinoma have still had bad prognosis despite advances in the modern treatment era.
  • From July 2005 to July 2008, 37 advanced gastric cancer patients treated with at least one course of mDCF protocol as first-line treatment were included.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3217-23 [17664469.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):536-40 [1548518.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3721-8 [12963704.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] JAMA. 1985 Apr 12;253(14):2061-7 [2579257.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1310-7 [2671287.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • (PMID = 19633962.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


96. Assumpção PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimarães AC, Calcagno DQ, Khayat AS, Demachki S, Smith Mde A, Burbano RR: Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet; 2006 Aug;169(1):45-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma.
  • Gastric cancer is the third most frequent type of neoplasia and the second most important cause of cancer-related death in the world.
  • To evaluate chromosomal aberrations implicated in gastric carcinogenesis, we analyzed 16 samples of gastric adenocarcinoma by fluorescence in situ hybridization using a chromosome 8 alpha-satellite probe and by direct chromosomal analysis techniques.
  • There was no significant difference between chromosome 8 ploidy and localization, stage, or histological type of adenocarcinoma in our sample.
  • Additional investigations are necessary to confirm the involvement of chromosome 8 and to identify genes in this chromosome related to gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 8. In Situ Hybridization, Fluorescence. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875936.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Al-Refaie WB, Tseng JF, Gay G, Patel-Parekh L, Mansfield PF, Pisters PW, Yao JC, Feig BW: The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer; 2008 Aug 1;113(3):461-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base.
  • BACKGROUND: Regional-based studies have indicated that ethnicity is associated with presentation and outcome in patients with gastric adenocarcinoma.
  • RESULTS: Between 1995 and 2002, 81,095 cases of gastric adenocarcinoma were entered into the NCDB.
  • In patients with stage I and II disease, the 5-year relative survival rates for APIs (stage I, 77.2%; stage II, 48%) were more favorable than for whites (stage I, 58.7%; stage II, 32.8%), African Americans (stage I, 55.9%; stage II, 37.9%), and Hispanics (stage I, 60.8%; stage II, 39.3%).
  • Predictors of a better outcome were Asian race, female sex, younger age, earlier stage, lower grade, distal tumors, multimodality treatment, and care at a teaching hospital.
  • CONCLUSIONS: Ethnicity was associated with differences in presentation and outcome of patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / ethnology. Databases, Factual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • (PMID = 18553367.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Büyükçelik A, Onur H, Akbulut H, Bülent Y, Ensari A, Utkan G, Onal BS, Içli F: Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori; 2005 Jul-Aug;91(4):302-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
  • AIMS AND BACKGROUND: We evaluated the prognostic value of p53 protein, DNA content and S-phase fraction in patients with adenocarcinoma of the stomach or the gastroesophageal junction treated with adjuvant etoposide, doxorubicin and cisplatin.
  • METHODS AND STUDY DESIGN: Thirty-five consecutive patients with stage II or III gastric or gastroesophageal junction adenocarcinoma treated with at least two cycles of adjuvant etoposide, doxorubicin and cisplatin after curative gastric resection were included.
  • P53 expression was detected in 42.9% (15 of 35) of gastric cancer tissues of the patients.
  • CONCLUSIONS: This trial supports the results of previous reports that p53 immunoreactivity is a prognostic factor for patients with adenocarcinoma of stomach or gastroesophageal junction treated with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Flow Cytometry. Stomach Neoplasms / drug therapy. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277093.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


99. Aurello P, Rossi S, D'Angelo F, Nigri G, Cicchini C, Ciardi A, Coluccia P, Ercolani G, Cescon M, Cucchetti A, Ravaioli M, Del Gaudio M, Ramacciato G: [Angiogenic factors and their relation to stage, lymph-node micrometastases and prognosis in patients operated on for gastric cancer]. Chir Ital; 2007 Jul-Aug;59(4):435-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiogenic factors and their relation to stage, lymph-node micrometastases and prognosis in patients operated on for gastric cancer].
  • [Transliterated title] Fattori angiogenici, apoptosi e loro correlazione con lo stadio, le micrometastasi linfonodali e la prognosi nei pazienti operati per cancro gastrico.
  • Angiogenic factors and apoptosis were studied immunohistochemically in 72 gastric cancer cases.
  • The apoptotic index was related to both stage and prognosis: high expression cases showed an earlier stage (p < 0.02) and a better prognosis (p < 0.05).
  • [MeSH-major] Adenocarcinoma / secondary. Apoptosis. Biomarkers, Tumor / analysis. Lymph Nodes / pathology. Stomach Neoplasms / pathology. Transforming Growth Factor alpha / analysis. Vascular Endothelial Growth Factors / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966762.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transforming Growth Factor alpha; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


100. Deng J, Liang H, Sun D, Wang D, Pan Y: Suitability of 7th UICC N stage for predicting the overall survival of gastric cancer patients after curative resection in China. Ann Surg Oncol; 2010 May;17(5):1259-66
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suitability of 7th UICC N stage for predicting the overall survival of gastric cancer patients after curative resection in China.
  • BACKGROUND: Metastatic lymph node count (MLNC) is the most intensively prognostic indicator of gastric cancer.
  • The purpose of this study was to evaluate the overall survival (OS) prediction of new UICC N stage in gastric cancer after curative surgery.
  • MATERIALS AND METHODS: Data from 456 patients who underwent curative resection were used to choose the most efficient classification of MLNC for evaluation the OS of gastric cancer.
  • RESULTS: Using univariate analysis, both the N stage of 7th edition UICC TNM classification (7th UICC N stage) and N stage of 5th/6th edition UICC TNM classification (5th/6th UICC N stage) were associated with the OS of gastric cancer after curative surgery.
  • However, Cox regression multivariate analysis showed the 7th UICC N stage was an independent factor for predicting the OS of gastric cancer instead of the 5th/6th UICC N stage.
  • Besides, we used the case-control matched fashion for further validation of the superiority of the 7th UICC N stage in prognostic prediction of gastric cancer.
  • Last, we adopted the cut-point survival analysis to determine the most appropriate cutoffs for MLNC of all gastric cancer patients after curative surgery.
  • We demonstrated the cutoff of 7th UICC N stage was similar to that produced from the cut-point survival analysis.
  • CONCLUSION: The 7th UICC N stage appears to provide a reliable prognostic category of MLNC of gastric cancer than the 5th/6th UICC N stage, and it is the efficiently prognostic indicator of gastric cancer after curative surgery.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Gastrectomy. Lymph Node Excision. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20217252.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement